glycerol and Obesity studies

Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research Excerpts

Excerpt	Relevance	Reference
"3 ng/mL, means +/- SE), the clinical and metabolic effects of benfluorex (B), a lipid-lowering drug able to improve insulin sensitivity."	9.08	Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. ( Camisasca, R; Cassisa, C; Pacchioni, M; Piatti, PM; Pontiroli, AE; Pozza, G, 1996)
" To examine how administration of the anti-inflammatory compound indomethacin, a general cyclooxygenase inhibitor, affected obesity development and insulin sensitivity, we fed obesity-prone male C57BL/6J mice a high fat/high sucrose (HF/HS) diet or a regular diet supplemented or not with indomethacin (±INDO) for 7 weeks."	7.80	Indomethacin treatment prevents high fat diet-induced obesity and insulin resistance but not glucose intolerance in C57BL/6J mice. ( Aune, UL; Borkowski, K; Fjære, E; Haj, FG; Hudson, BD; Keenan, AH; Kristensen, DM; Kristiansen, K; Liaset, B; Ma, T; Madsen, L; Mandrup-Poulsen, T; Milligan, G; Newman, JW; Novotny, GW; Røen, K; Xi, Y, 2014)
"To observe the antiobesity activity of trans-10,cis-12-conjugated linoleic acid (CLA)-producing lactobacillus in mice."	7.74	Antiobesity effect of trans-10,cis-12-conjugated linoleic acid-producing Lactobacillus plantarum PL62 on diet-induced obese mice. ( Lee, HY; Lee, K; Lee, Y; Paek, K; Park, JH, 2007)
"There is increasing evidence that the glycerol channel, aquaporin 7(AQP7), has an important role in adipose tissue formation and function--deletion of the gene in a mouse strain leads to obesity and diabetes type 2 if the mice are aged or fed earlier with a high-fat or sucrose diet."	7.73	Glycerol transport: an additional target for obesity therapy? ( Henry, BA; Wintour, EM, 2006)
"Our goal was to determine whether sex and abdominal obesity affect VLDL-triacylglycerol kinetics."	7.72	Effect of sex and obesity on basal VLDL-triacylglycerol kinetics. ( Klein, S; Mittendorfer, B; Patterson, BW, 2003)
"To determine the metabolic alterations that lead to the neonatal administration of monosodium glutamate (MSG), which results in arrested growth and obesity."	7.71	Decreased lipolysis and enhanced glycerol and glucose utilization by adipose tissue prior to development of obesity in monosodium glutamate (MSG) treated-rats. ( Dolnikoff, M; Herrera, E; Lima, FB; Machado, UF; Martín-Hidalgo, A, 2001)
"To study the initial period of fat deposition in human obesity, we measured glycerol turnover in 12 children of 135-253% ideal body weight, who had continuously gained weight since the onset of obesity 2-9 yr previously."	7.68	Glycerol production and utilization during the early phase of human obesity. ( Bougnères, PF; Le Stunff, C, 1992)
"The rate of lipolysis (glycerol Ra), gluconeogenesis from glycerol, and its contribution to overall hepatic glucose production (glucose Ra) were determined in 10 patients with noninsulin-dependent diabetes mellitus (NIDDM) [body mass index (BMI) 27."	7.68	Lipolysis and gluconeogenesis from glycerol are increased in patients with noninsulin-dependent diabetes mellitus. ( Koivisto, VA; Puhakainen, I; Yki-Järvinen, H, 1992)
"Neoadjuvant treatment with gemcitabine, cisplatin, and nab-paclitaxel is feasible and safe prior to resection of intrahepatic cholangiocarcinoma and does not adversely impact perioperative outcomes."	6.79	( Abbey, L; Abdelghany, TM; Abdellatif, MH; Abdelmohsen, UR; Abduljaleel Alzawar, NS; Abid, MF; Abu Kasim, AFB; Abu Saad, H; Adolpho, LF; Agostini, F; Agrizii, AP; Ahmed, S; Akce, M; Åkesson, D; Al-Awaadh, AM; Al-Mutar, DMK; Al-Odayni, AB; Al-Rajhi, AMH; Alaaeldin, R; Alam, M; Alam, MM; Alanazi, MA; Alattar, H; Alawlaqi, MM; Aldebis, HK; Algehainy, NA; Almeida, AA; Aloisi, F; Alrahlah, A; Alsenani, F; Alshabib, A; Altemani, FH; Althagafi, A; Amari, A; Andronesi, AG; Antonyuk, M; Arantes, TD; Araújo, R; Arrotti, S; Asakura, T; Asib, N; Atlaskin, AA; Aung, MS; Axiaq, A; Azekawa, S; Bacon, S; Bagalagel, A; Balbinot, GS; Barnet, LS; Baroyi, SAHM; Barreto, F; Barth, Y; Barysheva, AV; Bassa, E; Basu, R; Basu, S; Bates, C; Bautista, LS; Beitl, K; Beloti, MM; Benatti, G; Benavent-Celma, C; Bentaher, A; Bergsland, N; Bernardino, AF; Bernhardt, A; Bhandari, RK; Bhaskaran, K; Bhate, K; Bhattacharjee, A; Bian, X; Bien, EM; Birch, M; Bishara, K; Biswas, JP; Bleha, R; Bocale, R; Bona, S; Boriani, G; Bouyssi, A; Bradley, D; Bravo-Sánchez, MG; Bressan, GC; Brik, A; Brizuela, A; Brockbank, KGM; Buchner, F; Bunc, M; Buscombe, JR; Butler, AJ; Buzaleh, AM; Buzin, MI; Cabrera-Capetillo, CA; Calvo, AM; Camerota, A; Campagna, G; Campisi, M; Cano, K; Cao, HST; Cardellini, S; Carvalho, AP; Carvalho, BCR; Castillo-Baltazar, OS; Cataldo, P; Chai, P; Chakraborty, S; Chalo, DM; Chan, MY; Chander, S; Changbunjong, T; Chappuis, CJF; Chee, RCH; Chen, C; Chen, CJ; Chen, E; Chen, M; Chen, X; Chen, Y; Cheng, HT; Cheng, MC; Cheow, HK; Chi, Y; Chirikova, NK; Chiu, SH; Cho, G; Cho, HR; Cho, S; Cho, SJ; Choe, A; Choe, YH; Chun, BS; Chun, Z; Cinque, A; Ciopec, M; Cladas, Y; Cleary, SP; Clermont, O; Cléroux, M; Cockburn, J; Collares, FM; Colombini-Ishikiriama, BL; Conn, BN; Cortina, JL; Cox, DRA; Crini, G; Croker, R; Cursaru, DL; Curtis, HJ; da Silva, KJG; Dalla Costa, T; Davy, S; de Araújo, BV; de Cassia Ribeiro Gonçalves, R; de Gaetano, F; de Gregorio, C; de Oliveira, MG; De Vera, MAT; de Vos, M; de-la-Fuente, I; Dell'Oca, I; Delles, M; Déméautis, T; Dempster, M; Deng, YH; Denisenko, Y; Descombes, C; Desideri, G; Devarbhavi, H; Devouassoux, G; Di Bella, G; Di Marco, F; Diao, Y; Dias, BB; Dilgin, Y; Dimopoulou, I; Dionísio, TJ; Dobrovic, A; Dokin, ES; Dolby, T; Dong, X; Dong, Y; Dou, SX; Douglas, IJ; Dousset, S; Du, Z; Duan, M; Duan, SB; Duke-Williams, O; Duteanu, N; Dutertre, S; Dutta, S; Dwyer, MG; Ebenbauer, J; Eggo, RM; El-Mordy, FMA; Elbhnsawi, NA; Elrehany, MA; Elshewemi, SS; Elwakil, BH; Emadzadeh, D; Eraso, E; Ermolenko, E; Erten, K; Ettorre, E; Evans, D; Evans, SJ; Faheem, M; Fallanza, M; Faramarzi, M; Faria, FAC; Faro, DC; Fatma, YS; Fazil, S; Feng, Y; Ferguson, J; Fernandes, MH; Fernández-Domínguez, M; Ferrari, LAL; Ferraz, EP; Ferreira, LC; Ferri, C; Fikry, M; Floris, M; Forbes, H; Fotouh, B; Franke, K; Freitas, AC; Freitas, GP; Frieboes, HB; Fu, B; Fu, Y; Fukina, DG; Fukuda, DH; Fukunaga, K; Fulham, GJ; Furlan, L; Furtado Mesa, M; Furtunescu, FL; Gabbieri, D; Ganash, M; Gebers, JC; Gehman, V; Ghaedi, A; Ghazali, NSM; Ghebrekristos, Y; Gil, J; Gilbert, NM; Gimenes, R; Giordano, L; Glehen, O; Godeau, C; Goh, SK; Goldacre, B; Gomes, AM; Gomes, MPO; Gomes, PS; Gomes, RMODS; Gómez-Coma, L; Grenho, L; Gu, Q; Gu, T; Gu, YC; Guiducci, V; Guillemin, JP; Guo, W; Guo, YW; Gur, E; Guridi, A; Guzmán-López, A; Gvozdenko, T; H Elmaidomy, A; Hagar, M; Haider, S; Han, JM; Hanratty, J; Hans, R; Haque, N; Harharah, HN; Harharah, RH; Harper, S; Hasegawa, N; Hassanin, AH; Hastuti, YP; Hatem, AE; He, R; He, Y; Heinemann, C; Heinmaa, I; Heinzl, F; Helfer, VE; Hester, F; Hickman, G; Hill, MA; Hill, WG; Hintze, V; Ho, JSY; Ho, LY; Hoang, T; Holzer, I; Houbraken, J; Hsu, CN; Hu, J; Hu, X; Hu, Y; Hua, T; Huang, Z; Hulme, WJ; Hunter, A; Ianăşi, C; Ibañez, R; Iezzi, R; Iliuță, L; Im, YM; Imran, M; Inglesby, P; Inguimbert, N; Iqbal, A; Izawa, N; Jahaj, E; Jain, S; Jakimovski, D; Jalal, MM; Jaroszuk-Ściseł, J; Jasim, DJ; Jauregizar, N; Javle, MM; Jędryczka, M; Ji, H; Jiang, Y; Jin, J; Johnson, NT; Joshi, S; Jullok, N; Kachapulula, PW; Kaczmarek, J; Kaczmarek-Szczepańska, B; Kadota, K; Kaji, M; Kakeji, Y; Kakizoe, S; Kakudidi, E; Kalitukha, L; Kamata, H; Kang, YJ; Kapinos, AA; Karakaya, S; Kashchenko, NI; Kasyanov, S; Kataky, R; Katati, B; Kato, G; Katsina, AU; Kaya, A; Kaya, H; Kazarina, OV; Ke, Y; Keenan, C; Keilson, JM; Keshavan, A; Keskinidou, C; Khalifa, MA; Khan, R; Khan, S; Kim, D; Kim, K; Kim, MS; Kim, SM; Kim, WH; Kim, Y; Kim, YJ; Kishimura, H; Kitagawa, RR; Klemenkova, ZS; Kloss, F; Kobayashi, N; Kohlhoff, M; Kong, WKF; Konsek, H; Kornaros, M; Kotanidou, A; Kovacs, S; Kraska, J; Kruppke, B; Kumagai, Y; Kumar, S; Kumari, R; Kuruva, V; Kuster, RM; Kusumoto, T; Kutyła, M; Kwon, JH; Kwon, SH; Kwong, KY; Kyser, AJ; Lackner, M; Lass-Flörl, C; Lauri, C; Lavandera, JV; Lee, BH; Lee, ECY; Lee, HJ; Lee, J; Lee, PS; Lee, S; Lee, SE; Lee, SY; Lefort, F; Leite, JPV; Leo, G; Leonard, R; Leow, AST; Lepori, N; Leyden, K; Leys, L; Ležaić, L; Li, D; Li, H; Li, J; Li, S; Li, TYW; Li, X; Li, XH; Li, Y; Li, Z; Li, ZH; Liao, S; Liaqat, K; Lim, H; Lin, BS; Lin, MY; Lin, NH; Lin, X; Lin, Y; Liu, C; Liu, H; Liu, HK; Liu, HX; Liu, P; Liu, R; Liu, T; Liu, X; Liu, Y; Lock, GA; Lokaj, G; Lopes, HB; Losi, V; Lotsios, NS; Low, KE; Lu, Z; Luhana, S; Luo, X; Luo, XQ; Lutz, MB; Lysova, AA; Lyssenko, KA; Macit, M; MacIver, B; MacKenna, B; Magalhães, GAP; Magnavacchi, P; Mahadevan, J; Mahboubi, A; Maher, SA; Mahipal, A; Mahmoud, MY; Maithel, SK; Makhtar, MMZ; Makurat-Kasprolewicz, B; Malysheva, YB; Mansourizadeh, A; Marek, EJ; Maresca-Fichter, H; Martin, JT; Maslov, AA; Mastora, Z; Mastroiacovo, D; Mastropetros, SG; Matei, D; Mathur, R; Matos, AO; Matsuda, Y; Maurya, SK; Mayor, Á; Mayrhofer, D; Mazzuco, AC; McCaffrey, J; McClure, T; McDonald, HI; Mchunu, NP; McLaggan, D; Mehrkar, A; Meilik, B; Melito, VA; Mellem, J; Mengozzi, A; Menotti, J; Mesquita, V; Miao, Z; Mihai, S; Miller, S; Minassian, C; Mirabile, A; Mitra, S; Mladin, G; Mo, Z; Moawad, H; Mohamed, EM; Mohammed, TJ; Mohanlall, V; Mohyeldin, RH; Moldovan, H; Monneret, G; Monopoli, DE; Monte, IP; Monteiro, JRB; Morgante, V; Mori, M; Morin-Crini, N; Morita, A; Morton, CE; Mrak, M; Muhammed, AP; Mulick, A; Muralidharan, V; Murthy, P; Muselli, M; Mustafa, S; Mysore Visweswariah, A; Nagao, G; Naicker, S; Nakagawara, K; Namgoong, B; Namkoong, H; Namukobe, J; Nasir, AA; Nasreen, SA; Natarajan, P; Nchiozem-Ngnitedem, VA; Necozione, S; Negrea, A; Negrea, P; Ngubane, S; Nguyen, TT; Nicke, A; Nightingale, E; Nistor, CL; Nitsch, D; Njapau, H; Noman, M; Novgorodtseva, T; Nowak, A; O'Connor, SR; Ofoe, R; Oh, K; Oh, TH; Oki, E; Olama, ZA; Olennikov, DN; Oliveira, GM; Omar, D; Ong, SJ; Orfanos, SE; Origa-Oryem, H; Orita, H; Ortiz, I; Ota, M; Ott, J; Otvagina, KV; Pacheco, N; Pacheco, RR; Padmanabhan, D; Pagan, JD; Pagnotta, PA; Palangi, V; Palanisamy, G; Palanisamy, K; Palanisamy, S; Pan, SG; Panaitescu, E; Pang, X; Panoutsakopoulos, V; Parera, VE; Park, JI; Park, JS; Park, SW; Park, Y; Park, YS; Parkash, O; Parry, J; Parry, JP; Paul, SK; Pavšič, N; Pałubicka, A; Persat, F; Petriz-Prieto, MA; Petukhov, AN; Pham, T; Pillay, S; Poh, KK; Ponomarev, II; Pontons-Melo, JC; Posa, A; Powell, E; Priya, AK; Punekar, R; Puppin Rontani, RM; Purushottam, M; Pusphanathan, K; Qi, JY; Qin, J; Qin, Z; Qiu, B; Qiu, X; Quattrini, G; Quindós, G; Qureshi, F; Rabbany, MA; Rac-Albu, M; Rac-Albu, ME; Rădulescu, BC; Rafatullah, M; Rajab, TK; Rajna, S; Ramanathan, M; Rao, D; Raviglione, D; Razorenov, DY; Redd, MJ; Rehman, W; Reig, M; Rentsch, CT; Ribeiro, LMS; Robles, D; Rocchi, S; Rocha, FG; Rodrigues, C; Rodrigues, LA; Rodrigues, RP; Roh, GH; Ronowska, A; Root, A; Rosa, AL; Rossi, R; Roy, S; Roy, VC; Rupji, M; Saber, EA; Sadarat, F; Saed, Y; Saeed, WS; Saeki, H; Saha, B; Saiwichai, T; Sakowicz-Burkiewicz, M; Sampedro, T; Sands, K; Santos, CF; Sari, M; Sathi, FA; Sauro, S; Sazanova, TS; Scafa-Udriște, A; Schoustra, SE; Schultze, A; Seo, DJ; Sevillano, E; Sezmis, G; Sgura, FA; Shah, NNAK; Shani, N; Shankarappa, B; Sharkey, LM; Sharma, VK; Sharp, C; Shehata, N; Shelton, N; Shieh, PB; Shimokawa, M; Shin, J; Shin, SH; Shin, YN; Shin, YR; Shipilova, A; Shoparwe, NF; Shukor, H; Sia, CH; Siddiqui, MH; Siddiqui, MR; Siena, V; Signore, A; Silwane, B; Siqueira-Sandrin, VS; Siregar, A; Sirignano, P; Sit, NW; Skidmore, S; Skupov, KM; Smeeth, L; Smoczer, C; Smolyanskiy, E; Sohn, H; Solodeev, I; Solovyev, A; Şomoghi, R; Song, F; Song, H; Song, Z; Souf, YM; Sousa, SC; Souza, MT; Steinbach-Rankins, JM; Stockton, J; Stout, JR; Su, K; Su, MZ; Suarez-Lopez, YA; Sukkurd, R; Sultanov, R; Sun, Y; Sun, Z; Supernak, M; Supriyono, E; Suroshe, SS; Suvorov, SS; Svera M Ianăşi, P; Switchenko, JM; Syarif, NY; Synytsya, A; Taherzadeh, MJ; Tain, YL; Tamburino, C; Tammam, OY; Tan, BYQ; Tan, H; Tan, S; Tanaka, H; Tang, R; Tang, X; Tang, Z; Taurino, M; Tazare, J; Teresi, L; Testro, A; Thanasoponkul, W; Thangarasu, S; Thavaselvam, D; Theodoro, RC; Theron, G; Thomas, RH; Thomson, JJ; Tian, X; Tian, Y; Tomaszewski, CA; Tomlinson, LA; Torres, CMME; Tóth, M; Trecourt, A; Trevisani, F; Trimarchi, G; Tristán, C; Truong, VK; Tsigkou, K; Tsutsumi, S; Ubukata, Y; Uehara, H; Uwamino, Y; Vahedi-Shahandashti, R; Valberg, SJ; Valderrama, C; Valdovinos-García, EM; Valsecchi, D; van Diepeningen, AD; van West, P; Vargas-Osuna, E; Vassall, M; Vassilaki, N; Vassiliou, AG; Vecino, X; Velez-Irizarry, D; Venkatesh, YN; Vignali, L; Virdis, A; Viswanath, B; Voisin, AS; Volkova, YA; Vorotyntsev, AV; Vorotyntsev, IV; Vtyurina, ES; Vu, DH; Waldridge, B; Walker, AJ; Wallon, M; Wang, B; Wang, G; Wang, H; Wang, J; Wang, LJ; Wang, S; Wang, T; Wang, X; Wang, Z; Warren, RM; Warren-Gash, C; Wei, SH; Weinstock-Guttman, B; Wekwejt, M; Wessjohann, LA; Wiesmann, HP; Williams, ZJ; Williamson, EJ; Wilson, M; Wing, K; Wong, AY; Wong, BKL; Woodward, S; Wozniak, KL; Wu, C; Wu, K; Wu, S; Wu, Y; Xiang, D; Xie, H; Xiong, X; Xu, C; Xu, H; Xu, J; Xu, WH; Xu, Y; Xun, T; Yamaguchi, S; Yan, P; Yan, W; Yan, Z; Yang, B; Yang, F; Yang, L; Yao, XB; Yasui, H; Yenesew, A; Yeo, LLL; Yeo, TC; Yi, S; Yin, F; Yip, JWL; Yoon, SH; Yoon, SJ; Yoshida, M; Yoshizumi, T; Young, LA; Yu, C; Yu, DD; Yu, F; Yu, H; Yu, JD; Yu, NJ; Yu, X; Yuan, Y; Yurenko, A; Yusof, YA; Zahedipoor, A; Zahran, EM; Zainuddin, NI; Zanatta, AC; Zanotto, ED; Zanozin, ID; Zavascki, AP; Zenke, M; Zhang, F; Zhang, G; Zhang, H; Zhang, J; Zhang, L; Zhang, MX; Zhang, NY; Zhang, Q; Zhang, W; Zhang, X; Zhang, XM; Zhao, F; Zhao, Q; Zhao, R; Zhao, Y; Zheng, J; Zheng, S; Zhou, L; Zhou, X; Zhu, H; Zivadinov, R; Žižek, D; Zuccoli, JR; Zwaan, BJ, 2023)
"Resveratrol is a natural compound that affects energy metabolism and mitochondrial function and serves as a calorie restriction mimetic, at least in animal models of obesity."	5.15	Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. ( Auwerx, J; Bilet, L; Blaak, E; Goossens, GH; Hesselink, MKC; Hoeks, J; Houtkooper, RH; Kersten, S; Konings, E; Kunz, I; Moonen-Kornips, E; Ryu, D; Schrauwen, P; Schrauwen-Hinderling, VB; Timmers, S; van de Weijer, T; van der Krieken, S, 2011)
"Obesity is characterised by increased triacylglycerol storage in adipose tissue."	5.13	Effect of beta-adrenergic stimulation on whole-body and abdominal subcutaneous adipose tissue lipolysis in lean and obese men. ( Blaak, EE; Frayn, KN; Goossens, GH; Jocken, JW; Pakbiers, MT; Saris, WH; Stegen, J; van Baak, M; van Hees, AM, 2008)
"Dairy calcium supplementation in overweight subjects with habitually low calcium intakes failed to alter fat metabolism and energy expenditure under resting conditions and during acute stimulation by caffeine or epinephrine."	5.13	Dairy calcium supplementation in overweight or obese persons: its effect on markers of fat metabolism. ( Acheson, KJ; Bortolotti, M; Loizon, E; Rudelle, S; Schneiter, P; Tappy, L; Vidal, H, 2008)
"3 ng/mL, means +/- SE), the clinical and metabolic effects of benfluorex (B), a lipid-lowering drug able to improve insulin sensitivity."	5.08	Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. ( Camisasca, R; Cassisa, C; Pacchioni, M; Piatti, PM; Pontiroli, AE; Pozza, G, 1996)
"Yohimbine, an alpha 2-receptor antagonist, was examined for its suitability in the treatment of obesity."	5.07	Does yohimbine act as a slimming drug? ( Jonderko, K; Kucio, C; Piskorska, D, 1991)
" The objectives of the present review were to discuss some genes that potentially modulate the risk of coronary artery disease in diabetes mellitus; to address how the genes' respective contributions could possibly influence the global risk assessment of coronary artery disease among diabetic patients; and to present simple clinical markers, such as plasma glycerol concentration and the 'hypertriglyceridemic waist' phenotype, that could help to identify high-risk individuals."	4.82	Genetic aspects of diabetes and its cardiovascular complications: contribution of genetics to risk assessment and clinical management. ( Després, JP; Gaudet, D; Poirier, P; St-Pierre, J; Vohl, MC, 2005)
"Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy."	4.40	Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023)
"The anti-obesity effects of resveratrol shown in rodents are not transposed into an efficient therapy of human obesity."	3.85	Pterostilbene Inhibits Lipogenic Activity similar to Resveratrol or Caffeine but Differently Modulates Lipolysis in Adipocytes. ( Belles, C; Briot, A; Carpéné, C; Fernández-Quintela, A; Gomez-Zorita, S; Portillo, MP, 2017)
" Obesity in rats was obtained by the use of fatty diet and then the influence of the test compounds on body weight, food and water intakes, lipid and glucose profiles and glycerol and cortisol levels were determinated."	3.83	Pyrrolidin-2-one derivatives may reduce body weight in rats with diet-induced obesity. ( Bednarski, M; Dudek, M; Głuch-Lutwin, M; Kazek, G; Knutelska, J; Kulig, K; Mordyl, B; Nowiński, L; Sapa, J; Zaręba, P; Zygmunt, M, 2016)
" Serum FFA (n = 3,306), plasma glycerol (n = 3,776), and insulin sensitivity index (HOMA-IR,n = 3,469) were determined."	3.81	Fatty Acids, Obesity and Insulin Resistance. ( Arner, P; Rydén, M, 2015)
" G0S2 loss significantly decreased relative body weight gain as compared with wild-type (WT) (G0S2(+/+)) mice, with a significant decrease in gonadal fat pad weight and a significant increase in serum glycerol levels."	3.80	Mice lacking G0S2 are lean and cold-tolerant. ( Dmitrovsky, E; Freemantle, S; Li, A; Lopez-Aguiar, AG; Lu, Y; Ma, T; Nattie, EE; Sekula, D, 2014)
" To examine how administration of the anti-inflammatory compound indomethacin, a general cyclooxygenase inhibitor, affected obesity development and insulin sensitivity, we fed obesity-prone male C57BL/6J mice a high fat/high sucrose (HF/HS) diet or a regular diet supplemented or not with indomethacin (±INDO) for 7 weeks."	3.80	Indomethacin treatment prevents high fat diet-induced obesity and insulin resistance but not glucose intolerance in C57BL/6J mice. ( Aune, UL; Borkowski, K; Fjære, E; Haj, FG; Hudson, BD; Keenan, AH; Kristensen, DM; Kristiansen, K; Liaset, B; Ma, T; Madsen, L; Mandrup-Poulsen, T; Milligan, G; Newman, JW; Novotny, GW; Røen, K; Xi, Y, 2014)
"Curcumin, an active component derived from dietary spice turmeric (Curcuma longa), has been demonstrated antihyperglycemic, antiinflammatory and hypocholesterolemic activities in obesity and diabetes."	3.78	Curcumin attenuates lipolysis stimulated by tumor necrosis factor-α or isoproterenol in 3T3-L1 adipocytes. ( Kong, PR; Li, Y; Li, YX; Wu, JF; Xie, XY, 2012)
" 3-octadecylglycerol (batyl alcohol) has been described as an inflammatory agent, whereas Conjugated Linoleic Acid (CLA) is considered effective against obesity."	3.76	In vitro study of the effect of diesterified alkoxyglycerols with conjugated linoleic acid on adipocyte inflammatory mediators. ( Arranz-Gutiérrez, E; Gómez-Asensio, C; Ocaña, A; Reglero, G; Señoráns, FJ; Torres, C, 2010)
"To observe the antiobesity activity of trans-10,cis-12-conjugated linoleic acid (CLA)-producing lactobacillus in mice."	3.74	Antiobesity effect of trans-10,cis-12-conjugated linoleic acid-producing Lactobacillus plantarum PL62 on diet-induced obese mice. ( Lee, HY; Lee, K; Lee, Y; Paek, K; Park, JH, 2007)
"Obesity is accompanied by impaired fasting glycerol release, lower HSL protein expression, and serine phosphorylation."	3.74	Hormone-sensitive lipase serine phosphorylation and glycerol exchange across skeletal muscle in lean and obese subjects: effect of beta-adrenergic stimulation. ( Blaak, EE; Goossens, GH; Jocken, JW; Kiens, B; Roepstorff, C; Saris, WH; van Baak, M; van der Baan, P, 2008)
" NNE prevented the increase in body weight, parametrial adipose tissue weight and liver triacylglycerol levels in mice with obesity induced by a high-fat diet."	3.73	Anti-obesity effect of Nelumbo nucifera leaves extract in mice and rats. ( Fukaya, Y; Hattori, E; Imai, S; Ohizumi, Y; Ono, Y, 2006)
"There is increasing evidence that the glycerol channel, aquaporin 7(AQP7), has an important role in adipose tissue formation and function--deletion of the gene in a mouse strain leads to obesity and diabetes type 2 if the mice are aged or fed earlier with a high-fat or sucrose diet."	3.73	Glycerol transport: an additional target for obesity therapy? ( Henry, BA; Wintour, EM, 2006)
"Our goal was to determine whether sex and abdominal obesity affect VLDL-triacylglycerol kinetics."	3.72	Effect of sex and obesity on basal VLDL-triacylglycerol kinetics. ( Klein, S; Mittendorfer, B; Patterson, BW, 2003)
"The effect of fasting on hormonal and metabolic variables was evaluated in normal rats and in rats with obesity induced by neonatal treatment with monosodium glutamate (MSG)."	3.69	Hormonal and metabolic adaptations to fasting in monosodium glutamate-obese rats. ( Andrade, IS; do Nascimento, CM; Dolnikoff, MS; Hirata, AE; Ribeiro, EB, 1997)
"The rate of lipolysis (glycerol Ra), gluconeogenesis from glycerol, and its contribution to overall hepatic glucose production (glucose Ra) were determined in 10 patients with noninsulin-dependent diabetes mellitus (NIDDM) [body mass index (BMI) 27."	3.68	Lipolysis and gluconeogenesis from glycerol are increased in patients with noninsulin-dependent diabetes mellitus. ( Koivisto, VA; Puhakainen, I; Yki-Järvinen, H, 1992)
"To study the initial period of fat deposition in human obesity, we measured glycerol turnover in 12 children of 135-253% ideal body weight, who had continuously gained weight since the onset of obesity 2-9 yr previously."	3.68	Glycerol production and utilization during the early phase of human obesity. ( Bougnères, PF; Le Stunff, C, 1992)
"The effect of neonatal sympathectomy with guanethidine (50 mg/kg for 3 wk) on the development of diet-induced obesity (DIO) was assessed by raising guanethidine-(G) or saline-treated (S) Sprague-Dawley rats in small litters (4-5 pups/dam) and feeding a high-calorie diet from weaning (n = 29-30) or by raising similarly treated rats in normal litters (10 pups/dam) and feeding chow from weaning (n = 29-30)."	3.67	Dietary obesity and neonatal sympathectomy. I. Effects on body composition and brown adipose. ( Levin, BE; Marquet, E; Sullivan, AC; Triscari, J, 1984)
" The metabolic response of lean and obese women to caffeine was studied to see if caffeine could be used to demonstrate the subnormal thermogenesis in obesity previously shown after standard meals or intravenous infusions of noradrenaline."	3.66	Caffeine: its effect on catecholamines and metabolism in lean and obese humans. ( Barrand, MA; Callingham, BA; James, WP; Jung, RT; Shetty, PS, 1981)
" Plasma FFA and glycerol levels were increased in hyperthyroidism and plasma FFA was slightly decreased in hypothyroid patients, but these variables were not significantly correlated with any parameter of triglyceride metabolism."	3.65	Plasma triglyceride metabolism in thyroid disease. ( Kekki, M; Nikkilä, EA, 1972)
"In metabolic obesity energy in triglyceride stores is not readily accessible, and lipolysis to free fatty acid and glycerol seems to be somehow restrained."	3.65	Prostaglandins and obesity. ( Curtis-Prior, PB, 1975)
"Obesity is one of the most important metabolic disorders of this century and is associated with a cluster of the most dangerous cardiovascular disease risk factors, such as insulin resistance and diabetes, dyslipidemia, and hypertension, collectively named Metabolic Syndrome."	3.01	Aquaporins in Obesity. ( da Silva, IV; Soveral, G, 2023)
"Abdominal obesity is one of the main modifiable risk factors of age-related cardiometabolic disease."	2.94	Lifestyle-Intervention-Induced Reduction of Abdominal Fat Is Reflected by a Decreased Circulating Glycerol Level and an Increased HDL Diameter. ( Akker, EBVD; Beekman, M; de Geus-Oei, LF; Deelen, J; Dibbets-Schneider, P; Feskens, EJM; Heemst, DV; Noordam, R; Rest, OV; Schutte, BAM; Slagboom, PE, 2020)
" However, in lean men, the dose-response relationship between isoproterenol and glycerol was shifted towards the left (P < 0."	2.73	Dissociation between adipose nitric oxide synthase expression and tissue metabolism. ( Adams, F; Boschmann, M; Engeli, S; Franke, G; Gorzelniak, K; Janke, J; Jordan, J; Luft, FC, 2007)
"DeltaGlycerol was less suppressed following the high-Ca meals but statistical significance was not achieved."	2.72	The acute effects of different sources of dietary calcium on postprandial energy metabolism. ( Cummings, NK; James, AP; Soares, MJ, 2006)
"The isoproterenol-induced increase in EGC was higher after the training."	2.71	Dynamic strength training improves insulin sensitivity and functional balance between adrenergic alpha 2A and beta pathways in subcutaneous adipose tissue of obese subjects. ( Berlan, M; Hejnova, J; Klimcakova, E; Lafontan, M; Langin, D; Majercik, M; Moro, C; Polak, J; Stich, V; Viguerie, N, 2005)
"Glycerol Ra values were the same when tracer was infused with either a syringe or peristaltic pump on day 1 and day 2: 4."	2.71	Are peristaltic pumps as reliable as syringe pumps for metabolic research? Assessment of accuracy, precision, and metabolic kinetics. ( Coggan, AR; Fields, DA; Klein, S; Mittendorfer, B; Mohammed, BS, 2004)
"Sibutramine treatment significantly increased resting metabolic rate compared to the placebo condition."	2.71	Comparison of the acute pharmacodynamic responses after single doses of ephedrine or sibutramine in healthy, overweight volunteers. ( Balderson, DE; Brouwer, KL; Lancaster, ME; Ng, C; Paulik, MA; Persky, AM; Song, MH, 2004)
"Five adults with type 2 diabetes underwent an oral glucose tolerance test (OGTT) on two separate occasions, at least 1 week apart."	2.70	Acute fructose administration improves oral glucose tolerance in adults with type 2 diabetes. ( Cherrington, AD; Davis, SN; Mann, SL; Moore, MC, 2001)
"Abdominal obesity is associated with reduced 24-h plasma GH concentrations."	2.70	Hyposomatotropism blunts lipolysis in abdominally obese women. ( Ackermans, MT; Arndt, JW; Buijs, MM; Burggraaf, J; Cohen, AF; Frölich, M; Langendonk, JG; Meinders, AE; Pijl, H; Romijn, JA; Sauerwein, HP; Schoemaker, RC, 2002)
"Obesity is associated with blunted growth hormone (GH) levels and pulsatility and elevated plasma free fatty acids (FFA) levels."	2.67	Acute pharmacologic blockade of lipolysis normalizes nocturnal growth hormone levels and pulsatility in obese subjects. ( Andreotti, AC; Caumo, A; Lanzi, R; Manzoni, MF; Moreschi, A; Pontiroli, AE, 1994)
"Obesity is one of the most important metabolic disorders of this century and is associated with a cluster of the most dangerous cardiovascular disease risk factors, such as insulin resistance and diabetes , dyslipidemia and hypertension , collectively named Metabolic Syndrome."	2.55	Aquaporins in Obesity. ( da Silva, IV; Soveral, G, 2017)
"Obesity is a major risk factor for insulin resistance and type 2 diabetes."	2.44	[Glyceroneogenesis and PEPCK-C: pharmacological targets in type 2 diabetes]. ( Benelli, C; Cadoudal, T; Forest, C; Fouque, F, 2008)
"Diabetes mellitus, hyperlipidemia, hypertension and atherosclerotic diseases have recently defined as typical life style-related diseases."	2.41	[Life style-related disease]. ( Matsuzawa, Y, 2001)
"Glycerol is a key metabolite for lipid accumulation in insulin-sensitive tissues."	1.91	Increased Aquaporin-7 Expression Is Associated with Changes in Rat Brown Adipose Tissue Whitening in Obesity: Impact of Cold Exposure and Bariatric Surgery. ( Becerril, S; Catalán, V; Cienfuegos, JA; da Silva, IV; Frühbeck, G; Gómez-Ambrosi, J; Hernández-Pardos, AW; Méndez-Giménez, L; Moncada, R; Ramírez, B; Rodríguez, A; Soveral, G; Valentí, V, 2023)
"Obesity is linked to cardiometabolic diseases, however non-obese individuals are also at risk for type 2 diabetes (T2D) and cardiovascular disease (CVD)."	1.91	Adipose tissue specific CCL18 associates with cardiometabolic diseases in non-obese individuals implicating CD4 ( Andersson, DP; Arner, P; Hofwimmer, K; Laurencikiene, J; Massier, L; Subramanian, N; Tavira, B, 2023)
"Obesity is associated with high risk of mortality globally because obesity is associated with development of diseases such as diabetes, dyslipidemia, fatty liver disease, hypertension, and cancer."	1.91	( Beak, JK; Choi, HJ; Choi, JW; Jeong, JB; Koh, EJ; Lee, JW; Ryu, GH, 2023)
"Pregnancy is characterized by progressive decreases in glucose insulin sensitivity."	1.72	Maternal Lipid Metabolism Is Associated With Neonatal Adiposity: A Longitudinal Study. ( Catalano, PM; Hauguel-de Mouzon, S; Kalhan, SC; Price, LL; Rojas-Rodriguez, R; Somogie, J, 2022)
"Obesity is a consequence of the increased storage of triacylglycerol (TG)."	1.72	Dysregulation of Placental Lipid Hydrolysis by High-Fat/High-Cholesterol Feeding and Gestational Diabetes Mellitus in Mice. ( Bradić, I; Kargl, J; Korbelius, M; Kratky, D; Kuentzel, KB; Mihalič, ZN; Pirchheim, A; Rainer, S, 2022)
"However, hyperinsulinemia is observed in subjects with normoglycaemia and thus the paradigm above should be reevaluated."	1.62	Hyperinsulinemia and insulin resistance in the obese may develop as part of a homeostatic response to elevated free fatty acids: A mechanistic case-control and a population-based cohort study. ( Becattini, B; Brogren, H; Fryk, E; Gan, LM; Jansson, PA; Lind, L; Mossberg, K; Olausson, J; Piazza, S; Provenzani, A; Schmelz, M; Solinas, G; Strindberg, L, 2021)
"Insulin resistance is a cornerstone of obesity-related complications such as type 2 diabetes, metabolic syndrome, and nonalcoholic fatty liver disease."	1.62	Inhibiting serotonin signaling through HTR2B in visceral adipose tissue improves obesity-related insulin resistance. ( Cha, HN; Choi, SH; Choi, W; Choi, WG; Hwang, I; Kim, H; Lee, SY; Lee, YK; Lim, A; Oh, TJ; Park, SY; Ryu, D; Shin, H; Suh, JM, 2021)
"Trichostatin A (TSA) is a novel histone deacetylase inhibitor (HDACI) that was recently reported to exert multiple pharmacological functions."	1.62	HDAC inhibitor Trichostatin A suppresses adipogenesis in 3T3-L1 preadipocytes. ( Hao, T; Jiang, H; Lv, X; Qiu, J; Tan, Y; Zhang, H, 2021)
"Obesity is often regarded as the primary cause of metabolic syndrome."	1.42	Deleted in breast cancer 1 limits adipose tissue fat accumulation and plays a key role in the development of metabolic syndrome phenotype. ( Chini, CC; Chini, EN; Escande, C; Kirkland, JL; Nin, V; Pirtskhalava, T; Tchkonia, T, 2015)
"To improve treatment of obesity, a contributing factor to multiple systemic and metabolic diseases, a better understanding of metabolic state and environmental stress at the cellular level is essential."	1.42	Three-dimensional spheroid cell model of in vitro adipocyte inflammation. ( Janorkar, AV; Tang, Y; Turner, PA; Weiss, SJ, 2015)
"Obesity is strongly related to type-2 diabetes (T2DM), but there is a subset of obese individuals that remains relatively insulin sensitive and metabolically healthy."	1.40	Increased systemic and adipose tissue inflammation differentiates obese women with T2DM from obese women with normal glucose tolerance. ( Berends, FJ; Ioan-Facsinay, A; Koning, F; Lips, MA; Pijl, H; Toes, R; van Beek, L; van Harmelen, V; Visser, A; Willems van Dijk, K, 2014)
"Seven obese nondiabetic women with postprandial hyperglycemia and nine lean healthy women were recruited."	1.37	Impaired delivery of insulin to adipose tissue and skeletal muscle in obese women with postprandial hyperglycemia. ( Jansson, PA; Lönnroth, P; Sandqvist, M; Schmelz, M; Strindberg, L, 2011)
"Obesity has reached epidemic proportions worldwide and is stimulated by the ready availability of food rich in fat and sugar (highly palatable diet)."	1.36	Effects of a highly palatable diet on lipid and glucose parameters, nitric oxide, and ectonucleotidases activity. ( Böhmer, AE; Knorr, L; Lesczinski, DN; Lhullier, F; Moreira, JD; Müller, AP; Oses, JP; Perry, ML; Souza, CG; Souza, DG; Souza, DO; Viola, GG, 2010)
"Obesity is a common and rapidly growing health problem today."	1.35	Human mesenteric adipose tissue plays unique role versus subcutaneous and omental fat in obesity related diabetes. ( Abrams, GA; Aprahamian, CJ; Chen, M; Clements, RH; Harmon, CM; Yang, YK, 2008)
"Obesity is a risk factor for type 2 diabetes in cats."	1.35	The impact of obesity, sex, and diet on hepatic glucose production in cats. ( Burgess, SC; Ferguson, DC; Glushka, J; Hoenig, M; Jin, ES; Jordan, ET; Kley, S; Olson, DE; Prestegard, JH; Waldron, M; Wu, S, 2009)
"Body weight was increased after 7 weeks on both obesigenic diets (44."	1.35	Persistent diet-induced obesity in male C57BL/6 mice resulting from temporary obesigenic diets. ( Gavrilova, O; Guo, J; Hall, KD; Jou, W, 2009)
"An artificial hyperinsulinemia, which was induced to delineate the potential interaction between elevated FFAs and hyperinsulinemia, revealed that hyperinsulinemia also increased FGF-21 levels in vivo, while rosiglitazone treatment had no effect."	1.35	Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21. ( Andres, J; Biedasek, K; Bobbert, T; Clemenz, M; Kintscher, U; Mai, K; Meinus, S; Möhlig, M; Pfeiffer, AF; Reinecke, F; Sabath, M; Spranger, J; Spuler, S; Weicht, J; Weickert, MO, 2009)
"In citalopram treated subjects, basal glucose and lactate concentrations were higher compared with controls or with the trimipramine treated group."	1.35	Metabolism in adipose tissue in response to citalopram and trimipramine treatment--an in situ microdialysis study. ( Adler, G; Alt, A; Ditschuneit, HH; Flechtner-Mors, M; Jenkinson, CP, 2008)
"Glycerol release was measured with a colorimetric endpoint method."	1.33	Adiponectin expression and adipose tissue lipolytic activity in lean and obese women. ( Bulló, M; García-Lorda, P; Salas-Salvadó, J, 2005)
"Obesity is associated with hyperlipidemia and enlarged intramyocellular triglyceride (imcTG) stores."	1.33	Fatty acids inhibit intramyocellular triglyceride synthesis and turnover acutely in high fat-fed obese rats. ( Guo, Z; Zhou, L, 2006)
"Sibutramine is a satiety-inducing serotonin-noradrenaline reuptake inhibitor that acts predominantly via its primary and secondary metabolites."	1.33	The primary amine metabolite of sibutramine stimulates lipolysis in adipocytes isolated from lean and obese mice and in isolated human adipocytes. ( Bailey, CJ; Jones, RB; Richardson, DK, 2006)
"To understand the role of hyperinsulinemia in intramyocellular (imc) triglyceride (TG) accumulation and in regulating imcTG turnover."	1.33	Muscle type-dependent responses to insulin in intramyocellular triglyceride turnover in obese rats. ( Guo, Z; Zhou, L, 2005)
"These observations suggest that acute hyperinsulinemia inhibits imcTG synthesis and thus does not appear to promote imcTG accumulation via the synthetic pathway, at least in the short term."	1.33	Acute hyperinsulinemia inhibits intramyocellular triglyceride synthesis in high-fat-fed obese rats. ( Guo, Z; Jensen, MD; Zhou, L, 2006)
"Octopamine treatment resulted in a 19% decrease in body weight gain, when compared to the 177 g gained by controls during the same period."	1.32	Moderate weight-lowering effect of octopamine treatment in obese Zucker rats. ( Bour, S; Carpéné, C; Prévot, D; Visentin, V, 2003)
"Abdominal obesity is associated with a blunted lipolytic response to fasting that may contribute to the preservation of adipose tissue mass."	1.32	Blunted lipolytic response to fasting in abdominally obese women: evidence for involvement of hyposomatotropism. ( Buijs, MM; Burggraaf, J; Cohen, AF; de Kam, ML; Frölich, M; Meinders, AE; Pijl, H; Romijn, JA; Sauerwein, HP; Wijbrandts, C, 2003)
"Trecadrine-treatment to obese animals appeared to improve the number of lymphocyte subpopulations (CD4+ and CD8+) as compared to those animals only receiving the high-fat diet, being the values of the trecadrine-treated animals on the high-fat diet similar to the control rats."	1.32	Effects of a beta3-adrenergic agonist on the immune response in diet-induced (cafeteria) obese animals. ( Lamas, O; Marti, A; Martínez, JA, 2003)
"Insulin resistance was assessed in vivo using the euglycemic hyperinsulinemic clamp technique."	1.31	Ethnic differences in the responsiveness of adipocyte lipolytic activity to insulin. ( Buthelezi, EP; Crowther, NJ; Gray, IP; Lönnroth, PN; van der Merwe, MT, 2000)
"Glycerol release was measured and used as lipolytic index."	1.31	Influence of heredity for obesity on adipocyte lipolysis in lean and obese subjects. ( Hellström, L; Reynisdottir, S, 2000)
"Weight loss was 2, 3, and 3 kg after 5, 10, and 20 days, respectively; all of the weight lost was body fat."	1.31	Effect of dietary energy restriction on glucose production and substrate utilization in type 2 diabetes. ( Christiansen, MP; Hellerstein, MK; Linfoot, PA; Neese, RA, 2000)
"Glycerol release was determined in isolated adipocytes using a standard luminometric assay."	1.31	Increased expression of eNOS protein in omental versus subcutaneous adipose tissue in obese human subjects. ( Andersson, K; Bringman, S; Elizalde, M; Hoffstedt, J; Ohlund, A; Rydén, M; van Harmelen, V, 2001)
"Glycerol release (GR) was used to assess the lipolytic rate and was highest in LW in the abdominal area [0 h: LW, 1."	1.31	Lactate and glycerol release from adipose tissue in lean, obese, and diabetic women from South Africa. ( Boyd, IH; Crowther, NJ; Gray, IP; Joffe, BI; Lönnroth, PN; Schlaphoff, GP; van der Merwe, MT, 2001)
"lean (n = 10) subjects and type 2 diabetes patients (n = 8) vs."	1.31	Measurements of interstitial muscle glycerol in normal and insulin-resistant subjects. ( Ekberg, K; Gudbjörnsdottir, S; Holmäng, A; Lönnroth, P; Sjöstrand, M; Strindberg, L, 2002)
"Obesity is a classical feature of patients with Gs deficiency, but the mechanism leading to fat accumulation has not been elucidated."	1.30	Resistance to the lipolytic action of epinephrine: a new feature of protein Gs deficiency. ( Adnot, P; Bougnères, P; Carel, JC; Chaussain, JL; Condamine, L; Garabédian, M; Le Stunff, C; Mallet, E, 1999)
"Glycerol release was lowered by metformin during the 3-h experiment (P<0."	1.30	Metformin inhibits catecholamine-stimulated lipolysis in obese, hyperinsulinemic, hypertensive subjects in subcutaneous adipose tissue: an in situ microdialysis study. ( Adler, G; Alt, A; Ditschuneit, HH; Flechtner-Mors, M; Jenkinson, CP, 1999)
"Obese persons with hypertension are at greater risk for diabetes and hyperlipidemia than normotensive obese persons."	1.30	Lipolytic sensitivity and response to fasting in normotensive and hypertensive obese humans. ( Klein, S; Townsend, RR, 1997)
"Glycerol release was measured and used as a lipolytic index."	1.30	Lipolytic catecholamine resistance linked to alpha 2-adrenoceptor sensitivity--a metabolic predictor of weight loss in obese subjects. ( Hagström-Toft, E; Hellström, L; Reynisdottir, S; Rössner, S, 1997)
" With chronic administration (6 wk), AUGs decreased 47 and 33% in obese and lean animals, respectively."	1.30	A1 adenosine receptor antagonism improves glucose tolerance in Zucker rats. ( Berkich, DA; Crist, GH; LaNoue, KF; Xu, B, 1998)
"Urea levels were highest in controls, and lowest in cafeteria rats fed from day 30, a consequence of the different setting of nitrogen sparing induced by the timing of initiation of cafeteria feeding."	1.29	Long-term effects of cafeteria diet feeding on young Wistar rats. ( Alemany, M; Arola, L; Salvadó, J; Segués, T, 1994)
"Furthermore, the occurrence of fasting hypoglycemia necessitates careful monitoring of postnatal blood glucose values."	1.27	Intrauterine growth and postnatal fasting metabolism in infants of obese mothers. ( Dunnington, R; Gross, T; Kliegman, R; Morton, S, 1984)
" The dose-response relationships of the alpha 2- and beta-selective agents clonidine and isoproterenol were not appreciably changed by caloric restriction."	1.27	Adrenergic regulation of lipolysis in abdominal adipocytes of obese subjects during caloric restriction: reversal of catecholamine action caused by relief of endogenous inhibition. ( Fischer, B; Kather, H; Schlierf, G; Wieland, E; Wirth, A, 1985)
"Cushing's syndrome was characterized by abdominal obesity and enlarged abdominal fat cells, with adipose tissue lipoprotein lipase activity elevated 2-3 times that in normal women and low lipolytic capacity."	1.27	Muscle and adipose tissue morphology and metabolism in Cushing's syndrome. ( Björntorp, P; Elfverson, J; Krotkiewski, M; Rebuffé-Scrive, M, 1988)
"Starvation was associated with an approx."	1.27	Antilipolytic effects of N6-phenylisopropyladenosine and prostaglandin E2 in fat-cells of obese volunteers before and during energy restriction. ( Fischer, B; Kather, H; Schlierf, G; Wieland, E, 1985)
"Glycerol was not a major contributor to glyceride-glycerol synthesis (3."	1.26	A comparison of the enzyme levels and the in vitro utilization of various substrates for lipogenesis in pair-fed lean and obese pigs. ( Herbein, JH; Martin, RJ, 1976)

Research

Studies (469)

Authors

Clinical Trials (20)

Trial Overview

Trial Outcomes

Change in Glycerol Enrichment

Timeframe	Studies, this research(%)	All Research%
pre-1990	188 (40.09)	18.7374
1990's	70 (14.93)	18.2507
2000's	115 (24.52)	29.6817
2010's	69 (14.71)	24.3611
2020's	27 (5.76)	2.80

Authors	Studies
Choi, WG	1
Choi, W	1
Oh, TJ	1
Cha, HN	1
Hwang, I	1
Lee, YK	1
Lee, SY	2
Shin, H	1
Lim, A	1
Ryu, D	2
Suh, JM	1
Park, SY	1
Choi, SH	1
Kim, H	3
Heil, LBB	1
Cruz, FF	1
Antunes, MA	1
Braga, CL	1
Agra, LC	1
Bose Leão, RM	1
Abreu, SC	1
Pelosi, P	1
Silva, PL	1
Rocco, PRM	1
Truelsen, SF	1
Missel, JW	1
Gotfryd, K	1
Pedersen, PA	1
Gourdon, P	1
Lindorff-Larsen, K	1
Hélix-Nielsen, C	1
Al-Mass, A	1
Poursharifi, P	1
Peyot, ML	1
Lussier, R	1
Levens, EJ	1
Guida, J	1
Mugabo, Y	1
Possik, E	1
Ahmad, R	1
Al-Mulla, F	1
Sladek, R	1
Madiraju, SRM	1
Prentki, M	1
van Krieken, PP	1
Roos, J	1
Fischer-Posovszky, P	1
Wueest, S	1
Konrad, D	1
Rydén, M	6
Andersson, DP	2
Kotopouli, MI	1
Stenberg, E	1
Näslund, E	2
Thorell, A	1
Sørensen, TIA	1
Arner, P	17
Rojas-Rodriguez, R	1
Price, LL	1
Somogie, J	1
Hauguel-de Mouzon, S	1
Kalhan, SC	1
Catalano, PM	1
Leachman, JR	1
Cincinelli, C	1
Ahmed, N	1
Dalmasso, C	1
Xu, M	1
Gatineau, E	1
Nikolajczyk, BS	1
Yiannikouris, F	1
Hinds, TD	1
Loria, AS	1
Bidne, KL	1
Uhlson, C	1
Palmer, C	1
Zemski-Berry, K	1
Powell, TL	1
Kuentzel, KB	1
Bradić, I	1
Mihalič, ZN	1
Korbelius, M	1
Rainer, S	1
Pirchheim, A	1
Kargl, J	1
Kratky, D	1
Da Eira, D	3
Jani, S	3
Ceddia, RB	3
da Silva, IV	3
Soveral, G	3
Alvarez-Jimenez, L	1
Moreno-Cabañas, A	1
Morales-Palomo, F	1
Ortega, JF	1
Mora-Rodriguez, R	1
Frühbeck, G	5
Méndez-Giménez, L	1
Becerril, S	2
Ramírez, B	2
Hernández-Pardos, AW	1
Cienfuegos, JA	1
Valentí, V	1
Moncada, R	1
Catalán, V	2
Gómez-Ambrosi, J	2
Rodríguez, A	3
Subramanian, N	1
Hofwimmer, K	1
Tavira, B	1
Massier, L	1
Laurencikiene, J	2
de Frutos, S	1
Griera, M	1
Lavín-López, MDP	1
Martínez-Rovira, M	1
Martínez-Rovira, JA	1
Rodríguez-Puyol, M	1
Rodríguez-Puyol, D	1
Choi, JW	1
Choi, HJ	1
Ryu, GH	1
Lee, JW	1
Beak, JK	1
Koh, EJ	1
Jeong, JB	1
Duke-Williams, O	1
Stockton, J	1
Shelton, N	1
Huang, Z	3
Guo, W	2
Martin, JT	1
McCaffrey, J	1
Hunter, A	1
Venkatesh, YN	1
Rajna, S	1
Suroshe, SS	1
Joshi, S	1
Chander, S	2
Nasir, AA	1
Syarif, NY	1
Omar, D	1
Asib, N	1
Solodeev, I	1
Meilik, B	1
Gur, E	1
Shani, N	1
Holzer, I	1
Ott, J	1
Beitl, K	1
Mayrhofer, D	1
Heinzl, F	1
Ebenbauer, J	1
Parry, JP	1
Hanratty, J	1
Keenan, C	1
O'Connor, SR	1
Leonard, R	1
Chi, Y	1
Ferguson, J	1
Axiaq, A	1
Miller, S	1
Bradley, D	1
Dempster, M	1
Trevisani, F	1
Di Marco, F	1
Quattrini, G	1
Lepori, N	1
Floris, M	1
Valsecchi, D	1
Giordano, L	1
Dell'Oca, I	1
Cardellini, S	1
Cinque, A	1
Mirabile, A	1
Karakaya, S	1
Dilgin, Y	1
Jakimovski, D	1
Qureshi, F	1
Ramanathan, M	1
Gehman, V	1
Keshavan, A	1
Leyden, K	1
Dwyer, MG	1
Bergsland, N	1
Weinstock-Guttman, B	1
Zivadinov, R	1
Hastuti, YP	1
Siregar, A	1
Fatma, YS	1
Supriyono, E	1
Chen, M	2
He, Y	3
Hu, X	1
Dong, X	3
Yan, Z	2
Zhao, Q	1
Li, J	10
Xiang, D	1
Lin, Y	1
Song, H	3
Bian, X	1
Xu, J	3
Yuan, Y	2
Wang, B	5
Zhang, Q	5
Wang, J	9
Wang, S	1
Li, Y	6
Yan, W	2
Kaji, M	1
Namkoong, H	1
Nagao, G	1
Azekawa, S	1
Nakagawara, K	1
Tanaka, H	1
Morita, A	1
Asakura, T	1
Kamata, H	1
Uwamino, Y	1
Yoshida, M	1
Fukunaga, K	1
Hasegawa, N	2
Gebers, JC	1
Abu Kasim, AFB	1
Fulham, GJ	1
Kwong, KY	1
Marek, EJ	1
Tazare, J	1
Walker, AJ	1
Tomlinson, LA	1
Hickman, G	1
Rentsch, CT	1
Williamson, EJ	1
Bhaskaran, K	1
Evans, D	1
Wing, K	1
Mathur, R	1
Wong, AY	1
Schultze, A	1
Bacon, S	1
Bates, C	1
Morton, CE	1
Curtis, HJ	1
Nightingale, E	1
McDonald, HI	1
Mehrkar, A	1
Inglesby, P	1
Davy, S	1
MacKenna, B	1
Cockburn, J	1
Hulme, WJ	1
Warren-Gash, C	1
Bhate, K	1
Nitsch, D	1
Powell, E	1
Mulick, A	1
Forbes, H	1
Minassian, C	1
Croker, R	1
Parry, J	1
Hester, F	1
Harper, S	1
Eggo, RM	1
Evans, SJ	1
Smeeth, L	1
Douglas, IJ	1
Goldacre, B	1
Tan, H	1
Gu, T	1
Chen, E	1
Punekar, R	1
Shieh, PB	1
Katsina, AU	1
Mihai, S	1
Matei, D	1
Cursaru, DL	1
Şomoghi, R	1
Nistor, CL	1
Song, Z	1
Hu, J	2
Liu, P	1
Sun, Y	5
Baroyi, SAHM	1
Yusof, YA	1
Ghazali, NSM	1
Al-Awaadh, AM	1
Kadota, K	1
Mustafa, S	1
Abu Saad, H	1
Shah, NNAK	1
Fikry, M	1
Mladin, G	1
Ciopec, M	1
Negrea, A	1
Duteanu, N	1
Negrea, P	1
Svera M Ianăşi, P	1
Ianăşi, C	1
Cox, DRA	1
McClure, T	1
Zhang, F	1
Wong, BKL	1
Testro, A	1
Goh, SK	1
Muralidharan, V	1
Dobrovic, A	1
Shankarappa, B	1
Mahadevan, J	1
Murthy, P	1
Purushottam, M	1
Viswanath, B	1
Jain, S	1
Devarbhavi, H	1
Mysore Visweswariah, A	1
Zhang, MX	1
Cheng, HT	1
Chiu, SH	1
Pillay, S	1
de Vos, M	1
Sohn, H	1
Ghebrekristos, Y	1
Dolby, T	1
Warren, RM	1
Theron, G	1
Furtado Mesa, M	1
Stout, JR	1
Redd, MJ	1
Fukuda, DH	1
Panoutsakopoulos, V	1
Bassa, E	1
Alawlaqi, MM	1
Al-Rajhi, AMH	1
Abdelghany, TM	1
Ganash, M	1
Moawad, H	1
Magalhães, GAP	1
Thomson, JJ	1
Smoczer, C	1
Young, LA	1
Matos, AO	1
Pacheco, RR	1
Souza, MT	1
Zanotto, ED	1
Puppin Rontani, RM	1
Pontons-Melo, JC	1
Balbinot, GS	1
Sauro, S	1
Collares, FM	1
Adolpho, LF	1
Ribeiro, LMS	1
Freitas, GP	1
Lopes, HB	1
Gomes, MPO	1
Ferraz, EP	1
Gimenes, R	1
Beloti, MM	1
Rosa, AL	1
Kato, G	1
Araújo, R	1
Rodrigues, C	1
Gomes, PS	1
Grenho, L	1
Fernandes, MH	1
Heinemann, C	1
Buchner, F	1
Lee, PS	1
Bernhardt, A	1
Kruppke, B	1
Wiesmann, HP	1
Hintze, V	1
Robles, D	1
Brizuela, A	1
Fernández-Domínguez, M	1
Gil, J	1
Alrahlah, A	1
Khan, R	1
Al-Odayni, AB	1
Saeed, WS	1
Bautista, LS	1
Haider, S	1
De Vera, MAT	1
Alshabib, A	1
Yu, X	3
Tang, R	1
Liu, T	3
Qiu, B	1
Wei, SH	1
Wang, LJ	1
Lin, MY	1
Lim, H	1
Ho, LY	1
Sit, NW	1
Suarez-Lopez, YA	1
Hatem, AE	1
Aldebis, HK	1
Vargas-Osuna, E	1
Furlan, L	1
Bona, S	1
Tóth, M	1
Chappuis, CJF	1
Cléroux, M	1
Descombes, C	1
Barth, Y	1
Lefort, F	1
Thanasoponkul, W	1
Changbunjong, T	1
Sukkurd, R	1
Saiwichai, T	1
Kim, K	2
Kim, D	1
Kwon, SH	1
Roh, GH	1
Lee, S	1
Lee, BH	1
Lee, SE	1
Helfer, VE	1
Dias, BB	1
Lock, GA	1
Tomaszewski, CA	1
Barnet, LS	1
Barreto, F	1
Zavascki, AP	1
de Araújo, BV	1
Dalla Costa, T	1
Arrotti, S	1
Sgura, FA	1
Monopoli, DE	1
Siena, V	1
Leo, G	1
Morgante, V	1
Cataldo, P	1
Magnavacchi, P	1
Gabbieri, D	1
Guiducci, V	1
Benatti, G	1
Vignali, L	1
Boriani, G	1
Rossi, R	1
Skidmore, S	1
Hill, MA	1
Bishara, K	1
Konsek, H	1
Kwon, JH	1
Brockbank, KGM	1
Rajab, TK	1
Chee, RCH	1
Lin, NH	1
Ho, JSY	1
Leow, AST	1
Li, TYW	1
Lee, ECY	1
Chan, MY	1
Kong, WKF	1
Yeo, TC	1
Chai, P	1
Yip, JWL	1
Poh, KK	1
Sharma, VK	1
Yeo, LLL	1
Tan, BYQ	1
Sia, CH	1
Mrak, M	1
Pavšič, N	1
Žižek, D	1
Ležaić, L	1
Bunc, M	1
Iliuță, L	1
Andronesi, AG	1
Rac-Albu, M	1
Rac-Albu, ME	1
Scafa-Udriște, A	1
Moldovan, H	1
Furtunescu, FL	1
Rădulescu, BC	1
Panaitescu, E	1
Shin, SH	1
Kim, SM	1
Cho, SJ	1
Choe, YH	1
Monte, IP	1
Faro, DC	1
Trimarchi, G	1
de Gaetano, F	1
Campisi, M	1
Losi, V	1
Teresi, L	1
Di Bella, G	1
Tamburino, C	1
de Gregorio, C	1
Alattar, H	1
Xu, H	4
Zenke, M	1
Lutz, MB	1
Ong, SJ	1
Sharkey, LM	1
Low, KE	1
Cheow, HK	1
Butler, AJ	1
Buscombe, JR	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging[NCT02833415]	Phase 4	40 participants (Actual)	Interventional	2016-03-31	Completed
Mechanistic Studies in Human Subcutaneous Adipose Tissue[NCT06065930]		45 participants (Anticipated)	Observational	2023-05-05	Recruiting
Effect of Acute or Chronic Ingestion of Sucralose on Serum Insulin in Young and Healthy Adults: a Randomized, Double-blind, Placebo-controlled Trial[NCT03703141]		95 participants (Actual)	Interventional	2016-09-27	Completed
Resistance Training Modulation of Fat Metabolism in Obese Postmenopausal Women[NCT05351476]		120 participants (Anticipated)	Interventional	2022-05-20	Recruiting
Recombinant Human Leptin Therapy Effects on Insulin Action[NCT01207934]		18 participants (Actual)	Interventional	1998-08-31	Completed
A Double-blind, Randomized, Placebo-controlled, Parallel Design Study to Evaluate the Effects of the Cardio Formulation on Oxidized LDL in Individuals Who Are Overweight to Mildly Obese and Otherwise Healthy[NCT04317287]		9 participants (Actual)	Interventional	2019-12-10	Terminated (stopped due to COVID-19 Pandemic)
The Effect of Resveratrol on Metabolism and Cardiovascular Risk Profile in Patients With Chronic Obstructive Pulmonary Disease (COPD)[NCT02245932]		23 participants (Actual)	Interventional	2015-01-31	Completed
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease[NCT01504854]	Phase 2	119 participants (Actual)	Interventional	2012-05-31	Completed
Effect of Resveratrol on Insulin Sensitivity and Metabolic Profile in Type 2 Diabetics[NCT01638780]		24 participants (Anticipated)	Interventional	2012-05-31	Active, not recruiting
Sex Steroids, Sleep, and Metabolic Dysfunction in Women[NCT00805207]		61 participants (Actual)	Interventional	2007-09-30	Completed
Factors Associated With Obesity in Adult Women: Respiratory Exchange Ratio, Heart Rate Variation and Body Image[NCT04029532]		121 participants (Actual)	Observational	2019-04-01	Completed
Taurine Supplementation and Physical Training Effects on Adipose Tissue Mitochondrial Energy Metabolism, and Blood Inflammation and Oxidative Stress in Obese Women[NCT04279600]		24 participants (Actual)	Interventional	2017-05-01	Completed
Regulation of Lipolysis by Insulin in Skeletal Muscle and Adipose Tissue in Type 2 Diabetes[NCT01680133]		20 participants (Actual)	Observational	2007-06-30	Completed
Study of Interaction Between Adipose and Muscle Tissues in the Control of Muscle Mitochondrial Functions[NCT00446745]		60 participants (Actual)	Observational	2006-04-30	Completed
New Electrophoretic Approaches in Studies of Obesity and Diabetes[NCT03189732]		10 participants (Actual)	Interventional	2015-10-01	Completed
Transcriptional and Epigenetic Program of PCOS Women[NCT04034706]		108 participants (Actual)	Observational	2020-01-31	Active, not recruiting
Body Composition and Lipid Metabolism at Rest and During Exercise: A Cross-Sectional Analysis.[NCT03029364]		200 participants (Anticipated)	Observational	2018-01-08	Active, not recruiting
Dried Fruit as a Means for Lowering the Glycemic Response to High Glycemic Index-carbohydrate Foods[NCT02960373]		10 participants (Anticipated)	Interventional	2016-11-30	Not yet recruiting
An Acute Randomized Dose-finding Equivalence Trial of Small, Catalytic Doses of Fructose and Allulose on Postprandial Carbohydrate Metabolism: The Fructose and Allulose Catalytic Effects (FACE) Study[NCT02459834]		50 participants (Actual)	Interventional	2015-11-30	Completed
A Randomized Trial Evaluating the Effects of One-Year Caloric Restriction and 12-Week Exercise Training Intervention in Obese Adults With Type 2 Diabetes: Emphasis on Metabolic Control and Resting Metabolic Rate[NCT03785379]		23 participants (Actual)	Interventional	2013-02-28	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

[U-13C3] glycerol enrichment in plasma blood glucose over time will be measured by nuclear magnetic resonance spectroscopy. This is a percentage change from baseline to follow up in the percent enrichment of exogenous glycerol in blood glucose. We are unable to report a measure of central tendency and dispersion as the outcome is a percent change in the area under the enrichment curve for each group between baseline and follow-up. There is no measure of central tendency for these measurements without bootstrapping, which was not performed. (NCT02833415)
Timeframe: 3 months

Baseline Glucose Disposal - a Measure of the Body's Ability to Process Sugars.

Intervention	Percentage change (Number)
Empagliflozin	6.5
Placebo	1.4

pre-treatment glucose disposal. In general, a high glucose disposal rate is a marker of healthy metabolic function. Glucose disposal is measured by tracking the amount of tagged glucose in the bloodstream over time. It is adjusted to subject body weight. (NCT01207934)
Timeframe: baseline

Baseline Plasma Leptin Concentrations

Intervention	mmol/kg body weight/minute (Mean)
Placebo	14.3
Low Dose Leptin	18.4
High Dose Leptin	16.7

Leptin is an endogenous hormone. Here we measure the pre-treatment concentration of naturally-occurring leptin in the blood. (NCT01207934)
Timeframe: baseline

Post-treatment Glucose Disposal. I.e. Glucose Disposal After Treatment With Leptin or Placebo.

Intervention	Micrograms/Liter (Mean)
Placebo	27
Low Dose Leptin	24
High Dose Leptin	35

This is a measure of the body's ability to metabolize sugar after treatment with either leptin or a placebo. We compare the effect of leptin therapy on insulin-mediated stimulation of glucose disposal with that of placebo. In general, a high glucose disposal rate is a marker of healthy metabolic function. Glucose disposal is measured by tracking the amount of tagged glucose in the bloodstream over time. It is adjusted to subject body weight. (NCT01207934)
Timeframe: fourteen days

Post-treatment Plasma Leptin Levels

Intervention	mmol/kg body weight/minute (Mean)
Placebo	17.5
Low Dose Leptin	20.7
High Dose Leptin	19.1

plasma leptin levels after fourteen days ingestion of either leptin or placebo. (NCT01207934)
Timeframe: fourteen days

Change From Baseline in Cerebrospinal Fluid Amyloid β40 Concentration at 52 Weeks

Intervention	Micrograms/Liter (Mean)
Placebo	25
Low Dose Leptin	76
High Dose Leptin	5024

Mean change from baseline in cerebrospinal fluid amyloid β40 concentration at 52 weeks (NCT01504854)
Timeframe: Baseline and Week 52

Change From Baseline in Volumetric Magnetic Resonance Imaging (MRI)

Intervention	ng/ml (Mean)
Resveratrol	6456
Placebo	5622

MRI will be used to assess the effect of treatment on rate of whole brain volume (NCT01504854)
Timeframe: Baseline and Week 52

Change in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)

Intervention	cm^3 (Mean)
Resveratrol	27
Placebo	10

The ADCS-ADL is an activities of daily living inventory developed by the ADCS to assess functional performance in participants with AD. The ADCS-ADL includes some items from traditional basic ADL tests (e.g., grooming, dressing, walking, bathing, feeding, toileting) as well as instrumental (complex) activities of daily living (e.g., shopping, preparing meals, using household appliances, keeping appointments, reading). This structured questionnaire is administered to the subject's caregiver/study partner. The range of this instrument is 0 to 78 with lower numbers indicating greater impairment. (NCT01504854)
Timeframe: Week 52

Number of Adverse Events

Intervention	units on a scale (Mean)
Resveratrol	6.3
Placebo	9.2

The safety and tolerability of treatment with resveratrol will be assessed by analysis of adverse events, including symptoms, abnormal findings on physical examinations, standard laboratory tests and PK analysis of resveratrol and its major metabolites. The frequencies of adverse events or laboratory abnormalities between the participants who receive resveratrol and those receiving placebo will be compared. (NCT01504854)
Timeframe: Baseline, Weeks 6, 13, 19, 26, 32, 39, 45, and 52

Comparison of the Response to Treatment of Resveratrol Based on ApoE Genotype

Basal, Postabsorptive Fractional Synthesis Rates of Muscle Protein Synthesis

Intervention	number of AEs (Number)
Resveratrol	355
Placebo	302

Intervention	ng/ml (Mean)
	Total Population	ApoE4 non-carriers
Placebo	6560	6339
Resveratrol	6574	5859

"The fractional synthesis rate (FSR) of muscle protein synthesis was determined by assessing the incorporation of [5,5,5-2H3]leucine into muscle proteins. [5,5,5-2H3]leucine was infused for 5 hours with muscle biopsies obtained from the vastus lateralis muscle in the thigh 2 and 5 hours. The leucine tracer-to-tracee ratio (TTR) in muscle protein and the muscle free leucine pool was determined by gas chromatography-mass spectrometry (GCMS) and the FSR of muscle proteins calculated using a standard precursor-product model.~The FSR was calculated as %/h, which reflects the percent of all proteins in the muscle that were synthesized (made) per hour." (NCT00805207)
Timeframe: Before and at the end of the intervention

Very-Low Density Lipoprotein-Triglyceride (VLDL-TG) Concentration

Intervention	%/h (Mean)
	Before	After
Control	0.064	0.067
Estrogen	0.063	0.063
Glucocorticoid	0.059	0.061
Progesterone - PCOS	0.049	0.083
Progesterone - Postmenopausal Women	0.054	0.085
Testosterone - Postmenopausal Women	0.056	0.079
Testosterone - Premenopausal Women	0.064	0.092

VLDL was isolated from plasma by ultracentrifugation with VLDL-TG concentration measured by using a colorimetric enzymatic kit (Sigma-Aldrich, St. Louis, MO). (NCT00805207)
Timeframe: Before and at the end of the interventions

Very-Low Density Lipoprotein-Triglyceride (VLDL-TG) Concentration

Intervention	mmol/L (Mean)
	Before
Control - Baseline Testing Only	0.32

Very-Low Density Lipoprotein-Triglyceride (VLDL-TG) Secretion Rate

Intervention	mmol/L (Mean)
	Before	After
Continuous Positive Airway Pressure	0.50	0.64
Control	0.30	0.28
Estrogen	0.50	0.35
Glucocorticoid	0.35	0.33
Progesterone - PCOS	0.75	1.03
Progesterone - Postmenopausal Women	0.42	0.44
Testosterone - Postmenopausal Women	0.18	0.18
Testosterone - Premenopausal Women	0.31	0.40

VLDL was isolated from plasma by ultracentrifugation with the tracer-to-tracee (TTR) of free glycerol in plasma and glycerol in VLDL-TG determined by gas chromatography-mass spectrometry. The fractional turnover rates of VLDL-TG was determined by fitting the glycerol TTR time courses in plasma and in VLDL-TG to a multicompartmental model. The hepatic (liver) secretion rates of VLDL-TG was calculated by multiplying the fractional turnover rates of VLDL-TG by the of VLDL-TG concentration. (NCT00805207)
Timeframe: Before and at the end of interventions

Very-Low Density Lipoprotein-Triglyceride (VLDL-TG) Secretion Rate

Intervention	umol/min/L plasma (Mean)
	Before
Control - Baseline Testing Only	3.53

VLDL-TG Plasma Clearance Rate (Means)

Intervention	umol/min/L plasma (Mean)
	Before	After
Continuous Positive Airway Pressure	2.87	3.94
Control	2.47	2.57
Estrogen	2.87	2.94
Glucocorticoid	3.80	3.42
Progesterone - PCOS	4.66	7.77
Progesterone - Postmenopausal Women	3.36	3.24
Testosterone - Postmenopausal Women	2.03	2.11
Testosterone - Premenopausal Women	3.13	3.00

VLDL was isolated from plasma by ultracentrifugation with the tracer-to-tracee (TTR) of free glycerol in plasma and glycerol in VLDL-TG determined by gas chromatography-mass spectrometry. The fractional turnover rates of VLDL-TG was determined by fitting the glycerol TTR time courses in plasma and in VLDL-TG to a multicompartmental model. The plasma clearance rate of VLDL-TG was calculated by dividing the VLDL-TG secretion rate by the VLDL-TG concentration. (NCT00805207)
Timeframe: Before and at the end of the interventions

VLDL-TG Plasma Clearance Rate (Means)

Intervention	mL/min (Mean)
	Before
Control - Baseline Testing Only	33.1

VLDL was isolated from plasma by ultracentrifugation with the tracer-to-tracee (TTR) of free glycerol in plasma and glycerol in VLDL-TG determined by gas chromatography-mass spectrometry. The fractional turnover rates of VLDL-TG was determined by fitting the glycerol TTR time courses in plasma and in VLDL-TG to a multicompartmental model. The plasma clearance rate of VLDL-TG was calculated by dividing the VLDL-TG secretion rate by the VLDL-TG concentration. (NCT00805207)
Timeframe: Before and at the end of the interventions

VLDL-TG Plasma Clearance Rate (Medians)

Intervention	mL/min (Mean)
	Before	After
Continuous Positive Airway Pressure	19.1	20.8
Control	22.6	23.3
Estrogen	17.4	25.1
Glucocorticoid	33.8	34.3
Progesterone - PCOS	20.3	24.6
Progesterone - Postmenopausal Women	21.2	24.9
Testosterone - Postmenopausal Women	35.1	34.5
Testosterone - Premenopausal Women	42.2	58.1

VLDL was isolated from plasma by ultracentrifugation with the tracer-to-tracee (TTR) of free glycerol in plasma and glycerol in VLDL-TG determined by gas chromatography-mass spectrometry. The fractional turnover rates of VLDL-TG was determined by fitting the glycerol TTR time courses in plasma and in VLDL-TG to a multicompartmental model. The plasma clearance rate of VLDL-TG was calculated by dividing the VLDL-TG secretion rate by the VLDL-TG concentration. (NCT00805207)
Timeframe: Before and at the end of the interventions

VLDL-TG Plasma Clearance Rate (Medians)

Intervention	mL/min (Median)
	Before
Control - Baseline Testing Only	33.4

VLDL was isolated from plasma by ultracentrifugation with the tracer-to-tracee (TTR) of free glycerol in plasma and glycerol in VLDL-TG determined by gas chromatography-mass spectrometry. The fractional turnover rates of VLDL-TG was determined by fitting the glycerol TTR time courses in plasma and in VLDL-TG to a multicompartmental model. The plasma clearance rate of VLDL-TG was calculated by dividing the VLDL-TG secretion rate by the VLDL-TG concentration. (NCT00805207)
Timeframe: Before and at the end of the interventions

Article	Year
Aquaporins in Obesity. Advances in experimental medicine and biology, 2023, Volume: 1398 Topics: Aquaglyceroporins; Aquaporins; Glycerol; Humans; Insulin Resistance; Lipids; Metabolic Diseases; Obe	2023
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. Science & sports, 2023, Apr-04 Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp	2023
Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2023, Jun-08 Topics: Acetogenins; Acute Disease; Acute Kidney Injury; Administration, Intravenous; Aged; Albumins; Alcoho	2023
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
CIDE Family-Mediated Unique Lipid Droplet Morphology in White Adipose Tissue and Brown Adipose Tissue Determines the Adipocyte Energy Metabolism. Journal of atherosclerosis and thrombosis, 2017, Oct-01, Volume: 24, Issue:10 Topics: Adipocytes; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Apoptosis Regulatory Proteins; Di	2017
Glycerol and testicular activity: the good, the bad and the ugly. Molecular human reproduction, 2017, 11-01, Volume: 23, Issue:11 Topics: Adult; Aquaglyceroporins; Biological Transport; Gene Expression Regulation; Glycerol; Glycerophospha	2017
Mammalian aquaglyceroporin function in metabolism. Biochimica et biophysica acta, 2016, Volume: 1858, Issue:1 Topics: Adipose Tissue; Animals; Aquaglyceroporins; Biological Transport, Active; Diabetes Mellitus, Type 2;	2016
Aquaporins in Obesity. Advances in experimental medicine and biology, 2017, Volume: 969 Topics: Adipose Tissue; Aquaglyceroporins; Aquaporins; Energy Metabolism; Gene Expression Regulation; Glycer	2017
Role of aquaporin-7 and aquaporin-9 in glycerol metabolism; involvement in obesity. Handbook of experimental pharmacology, 2009, Issue:190 Topics: Adipocytes; Animals; Aquaglyceroporins; Aquaporins; Cloning, Molecular; Gluconeogenesis; Glycerol; H	2009
[Aquaporin adipose (AQPap)]. Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 1 Topics: Animals; Aquaporins; Glycerol; Humans; Obesity	2011
Sympathetic control of white adipose tissue in lean and obese humans. Acta physiologica Scandinavica, 2003, Volume: 177, Issue:3 Topics: Action Potentials; Adipose Tissue; Adrenergic alpha-Agonists; Animals; Electric Stimulation; Energy	2003
Genetic aspects of diabetes and its cardiovascular complications: contribution of genetics to risk assessment and clinical management. The Canadian journal of cardiology, 2005, Volume: 21, Issue:2 Topics: Albuminuria; Coronary Artery Disease; Diabetes Mellitus, Type 2; Genetic Predisposition to Disease;	2005
Role of aquaporin-7 in the pathophysiological control of fat accumulation in mice. FEBS letters, 2006, Sep-04, Volume: 580, Issue:20 Topics: Adipose Tissue; Animals; Aquaporins; Glucose; Glycerol; Homeostasis; Insulin Resistance; Mice; Obesi	2006
Impact of glycerol gateway molecule in adipocytes. Cellular and molecular biology (Noisy-le-Grand, France), 2006, Oct-30, Volume: 52, Issue:7 Topics: Adipocytes; Animals; Aquaporins; Biological Transport; Gene Expression Regulation; Glycerol; Humans;	2006
[Glyceroneogenesis and PEPCK-C: pharmacological targets in type 2 diabetes]. Medecine sciences : M/S, 2008, Volume: 24, Issue:4 Topics: Diabetes Mellitus, Type 2; Energy Metabolism; Fatty Acids; Glycerol; Humans; Insulin; Insulin Resist	2008
Autoregulation of endogenous glucose production in man. Biochemical Society transactions, 1997, Volume: 25, Issue:1 Topics: Amino Acids; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fructose; Gluconeogenesis; Glycerol; Glyc	1997
Investigation of human adipose tissue metabolism in vivo. The Journal of endocrinology, 1997, Volume: 155, Issue:2 Topics: Adipocytes; Adipose Tissue; Fatty Acids, Nonesterified; Glycerol; Humans; Obesity; Triglycerides	1997
Revisiting the role of fat mass in the life extension induced by caloric restriction. The journals of gerontology. Series A, Biological sciences and medical sciences, 1999, Volume: 54, Issue:3 Topics: Adipose Tissue; Aging; Animals; Complement System Proteins; Endocrine Glands; Energy Intake; Fatty A	1999
[Life style-related disease]. Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59, Issue:1 Topics: Adiponectin; Adipose Tissue; Arteriosclerosis; Diabetes Mellitus; Fatty Acids, Nonesterified; Glycer	2001
Insulin resistance in childhood obesity. Journal of pediatric endocrinology & metabolism : JPEM, 2002, Volume: 15 Suppl 1 Topics: Abdomen; Adipose Tissue; Adolescent; Body Composition; Cardiovascular Diseases; Child; Diabetes Mell	2002
Physiology and pathophysiology of glucagon. Physiological reviews, 1976, Volume: 56, Issue:4 Topics: Animals; Cattle; Cerebrovascular Circulation; Diabetes Mellitus; Diet; Dogs; Fatty Acids, Nonesterif	1976
[Effects of chronic inhibition of adipocyte phosphodiesterase on lipolysis induced with noradrenaline in normal and obese subjects]. Archivio "E. Maragliano" di patologia e clinica, 1978, Volume: 34, Issue:2 Topics: Adipose Tissue; Adult; Blood Glucose; Fatty Acids, Nonesterified; Female; Flavonoids; Flavoxate; Gly	1978
[Glucagon-induced lipolysis and obesity]. Archivio "E. Maragliano" di patologia e clinica, 1978, Volume: 34, Issue:1 Topics: Adult; Fatty Acids, Nonesterified; Female; Glucagon; Glycerol; Humans; Insulin; Lipid Metabolism; Mi	1978
Control of hepatic glyceride synthesis. The Proceedings of the Nutrition Society, 1975, Volume: 34, Issue:3 Topics: Animals; Carbohydrate Metabolism; Carnitine Acyltransferases; Coenzyme A; Coenzyme A Ligases; Dietar	1975
Therapeutic results of insulin therapy in gestational diabetes mellitus. Diabetes, 1985, Volume: 34 Suppl 2 Topics: 3-Hydroxybutyric Acid; Amino Acids; Birth Weight; Blood Glucose; Body Weight; Delivery, Obstetric; F	1985
Human adipose tissue dynamics and regulation. Advances in metabolic disorders, 1971, Volume: 5 Topics: Adipose Tissue; Cyclic AMP; Diabetes Mellitus; Epinephrine; Extracellular Space; Fatty Acids; Fatty	1971
Interactions between carbohydrate, protein, and fat metabolism in starvation. Nutrition reviews, 1969, Volume: 27, Issue:9 Topics: Alanine; Amino Acids; Ammonia; Carbohydrate Metabolism; Gluconeogenesis; Glycerol; Glycine; Humans;	1969

Article	Year
Chronic Statin Treatment Does Not Impair Exercise Lipolysis or Fat Oxidation in Exercise-Trained Individuals With Obesity and Dyslipidemia. International journal of sport nutrition and exercise metabolism, 2023, May-01, Volume: 33, Issue:3 Topics: Blood Glucose; Cholesterol; Dyslipidemias; Glucose; Glycerol; Humans; Hydroxymethylglutaryl-CoA Redu	2023
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. Science & sports, 2023, Apr-04 Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp	2023
Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2023, Jun-08 Topics: Acetogenins; Acute Disease; Acute Kidney Injury; Administration, Intravenous; Aged; Albumins; Alcoho	2023
Lifestyle-Intervention-Induced Reduction of Abdominal Fat Is Reflected by a Decreased Circulating Glycerol Level and an Increased HDL Diameter. Molecular nutrition & food research, 2020, Volume: 64, Issue:10 Topics: Abdominal Fat; Aged; Biomarkers; Body Composition; Caloric Restriction; Female; Glycerol; Humans; Li	2020
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P	2016
Effects of Empagliflozin Treatment on Glycerol-Derived Hepatic Gluconeogenesis in Adults with Obesity: A Randomized Clinical Trial. Obesity (Silver Spring, Md.), 2020, Volume: 28, Issue:7 Topics: Adipose Tissue; Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind	2020
Epigenetic Regulation of PLIN 1 in Obese Women and its Relation to Lipolysis. Scientific reports, 2017, 08-31, Volume: 7, Issue:1 Topics: Adipocytes, White; Adult; CpG Islands; DNA Methylation; Epigenesis, Genetic; Female; Glycerol; Human	2017
Comparing olive oil and C4-dietary oil, a prodrug for the GPR119 agonist, 2-oleoyl glycerol, less energy intake of the latter is needed to stimulate incretin hormone secretion in overweight subjects with type 2 diabetes. Nutrition & diabetes, 2018, 01-12, Volume: 8, Issue:1 Topics: Aged; Area Under Curve; Diabetes Mellitus, Type 2; Dietary Fats, Unsaturated; Female; Gastric Inhibi	2018
Acute effect on satiety, resting energy expenditure, respiratory quotient, glucagon-like peptide-1, free fatty acids, and glycerol following consumption of a combination of bioactive food ingredients in overweight subjects. Journal of the American College of Nutrition, 2013, Volume: 32, Issue:1 Topics: Adult; Alkaloids; Area Under Curve; Basal Metabolism; Benzodioxoles; Capsaicin; Carnitine; Catechin;	2013
Does continuous endurance exercise in water elicit a higher release of ANP and BNP and a higher plasma concentration of FFAs in pre-obese and obese men than high intensity intermittent endurance exercise? - study protocol for a randomized controlled trial Trials, 2013, Oct-10, Volume: 14 Topics: Atrial Natriuretic Factor; Biomarkers; Cross-Over Studies; Exercise Therapy; Fatty Acids, Nonesterif	2013
Alkylglycerols reduce serum complement and plasma vascular endothelial growth factor in obese individuals. Inflammopharmacology, 2016, Volume: 24, Issue:2-3 Topics: Adult; Anti-Inflammatory Agents; Biomarkers; Cross-Over Studies; Double-Blind Method; Female; Fish O	2016
The Effect of Casein Protein Prior to Sleep on Fat Metabolism in Obese Men. Nutrients, 2016, Jul-27, Volume: 8, Issue:8 Topics: Adolescent; Adult; Appetite Regulation; Biomarkers; Body Mass Index; Caseins; Cross-Over Studies; Di	2016
Dairy calcium supplementation in overweight or obese persons: its effect on markers of fat metabolism. The American journal of clinical nutrition, 2008, Volume: 88, Issue:4 Topics: Adipose Tissue; Adult; Basal Metabolism; Biomarkers; Caffeine; Calcium; Calcium, Dietary; Cross-Over	2008
Effect of the dietary supplement Meltdown on catecholamine secretion, markers of lipolysis, and metabolic rate in men and women: a randomized, placebo controlled, cross-over study. Lipids in health and disease, 2009, Aug-05, Volume: 8 Topics: Adipose Tissue; Analysis of Variance; Anti-Obesity Agents; Area Under Curve; Biomarkers; Caffeine; C	2009
Effect of carbohydrate- and protein-rich meals on exercise-induced activation of lipolysis in obese subjects. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2010, Volume: 42, Issue:4 Topics: Adult; Blood Glucose; Dietary Carbohydrates; Dietary Proteins; Exercise; Fasting; Female; Food; Glyc	2010
Lipid mobilization in subcutaneous adipose tissue during exercise in lean and obese humans. Roles of insulin and natriuretic peptides. American journal of physiology. Endocrinology and metabolism, 2010, Volume: 299, Issue:2 Topics: Adipose Tissue; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adrenergic beta-Ant	2010
Effects of dietary fat modification on insulin sensitivity and on other risk factors of the metabolic syndrome--LIPGENE: a European randomized dietary intervention study. International journal of obesity (2005), 2011, Volume: 35, Issue:6 Topics: Diet, Fat-Restricted; Dietary Fats; Energy Intake; Europe; Fatty Acids; Fatty Acids, Unsaturated; Fe	2011
Increased adipose tissue lipolysis after a 2-week high-fat diet in sedentary overweight/obese men. Metabolism: clinical and experimental, 2011, Volume: 60, Issue:7 Topics: Adolescent; Adult; Cholesterol; Cholesterol, HDL; Dietary Fats; Glycerol; Humans; Lipolysis; Male; M	2011
Galactose promotes fat mobilization in obese lactating and nonlactating women. The American journal of clinical nutrition, 2011, Volume: 93, Issue:2 Topics: Adult; Anti-Obesity Agents; Blood Glucose; Breast Feeding; Cross-Over Studies; Dietary Sucrose; Fema	2011
Recombinant human leptin treatment does not improve insulin action in obese subjects with type 2 diabetes. Diabetes, 2011, Volume: 60, Issue:5 Topics: Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glycero	2011
Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell metabolism, 2011, Nov-02, Volume: 14, Issue:5 Topics: Adipose Tissue; Alanine Transaminase; AMP-Activated Protein Kinase Kinases; Blood Glucose; Blood Pre	2011
Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell metabolism, 2011, Nov-02, Volume: 14, Issue:5 Topics: Adipose Tissue; Alanine Transaminase; AMP-Activated Protein Kinase Kinases; Blood Glucose; Blood Pre	2011
Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell metabolism, 2011, Nov-02, Volume: 14, Issue:5 Topics: Adipose Tissue; Alanine Transaminase; AMP-Activated Protein Kinase Kinases; Blood Glucose; Blood Pre	2011
Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell metabolism, 2011, Nov-02, Volume: 14, Issue:5 Topics: Adipose Tissue; Alanine Transaminase; AMP-Activated Protein Kinase Kinases; Blood Glucose; Blood Pre	2011
Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell metabolism, 2011, Nov-02, Volume: 14, Issue:5 Topics: Adipose Tissue; Alanine Transaminase; AMP-Activated Protein Kinase Kinases; Blood Glucose; Blood Pre	2011
Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell metabolism, 2011, Nov-02, Volume: 14, Issue:5 Topics: Adipose Tissue; Alanine Transaminase; AMP-Activated Protein Kinase Kinases; Blood Glucose; Blood Pre	2011
Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell metabolism, 2011, Nov-02, Volume: 14, Issue:5 Topics: Adipose Tissue; Alanine Transaminase; AMP-Activated Protein Kinase Kinases; Blood Glucose; Blood Pre	2011
Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell metabolism, 2011, Nov-02, Volume: 14, Issue:5 Topics: Adipose Tissue; Alanine Transaminase; AMP-Activated Protein Kinase Kinases; Blood Glucose; Blood Pre	2011
Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell metabolism, 2011, Nov-02, Volume: 14, Issue:5 Topics: Adipose Tissue; Alanine Transaminase; AMP-Activated Protein Kinase Kinases; Blood Glucose; Blood Pre	2011
Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell metabolism, 2011, Nov-02, Volume: 14, Issue:5 Topics: Adipose Tissue; Alanine Transaminase; AMP-Activated Protein Kinase Kinases; Blood Glucose; Blood Pre	2011
Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell metabolism, 2011, Nov-02, Volume: 14, Issue:5 Topics: Adipose Tissue; Alanine Transaminase; AMP-Activated Protein Kinase Kinases; Blood Glucose; Blood Pre	2011
Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell metabolism, 2011, Nov-02, Volume: 14, Issue:5 Topics: Adipose Tissue; Alanine Transaminase; AMP-Activated Protein Kinase Kinases; Blood Glucose; Blood Pre	2011
Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell metabolism, 2011, Nov-02, Volume: 14, Issue:5 Topics: Adipose Tissue; Alanine Transaminase; AMP-Activated Protein Kinase Kinases; Blood Glucose; Blood Pre	2011
Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell metabolism, 2011, Nov-02, Volume: 14, Issue:5 Topics: Adipose Tissue; Alanine Transaminase; AMP-Activated Protein Kinase Kinases; Blood Glucose; Blood Pre	2011
Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell metabolism, 2011, Nov-02, Volume: 14, Issue:5 Topics: Adipose Tissue; Alanine Transaminase; AMP-Activated Protein Kinase Kinases; Blood Glucose; Blood Pre	2011
Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell metabolism, 2011, Nov-02, Volume: 14, Issue:5 Topics: Adipose Tissue; Alanine Transaminase; AMP-Activated Protein Kinase Kinases; Blood Glucose; Blood Pre	2011
Hyposomatotropism blunts lipolysis in abdominally obese women. The Journal of clinical endocrinology and metabolism, 2002, Volume: 87, Issue:8 Topics: Abdomen; Adipose Tissue; Body Mass Index; Female; Glycerol; Human Growth Hormone; Humans; Hypopituit	2002
Modeling the influence of growth hormone on lipolysis. Journal of pharmacokinetics and pharmacodynamics, 2002, Volume: 29, Issue:2 Topics: Cross-Over Studies; Double-Blind Method; Glycerol; Growth Hormone; Humans; Lipolysis; Models, Biolog	2002
Post-exercise increase of lipid oxidation after a moderate exercise bout in untrained healthy obese men. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2003, Volume: 35, Issue:2 Topics: Adult; Blood Glucose; Body Mass Index; Cross-Over Studies; Epinephrine; Exercise; Fatty Acids, Nones	2003
Post-exercise increase of lipid oxidation after a moderate exercise bout in untrained healthy obese men. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2003, Volume: 35, Issue:2 Topics: Adult; Blood Glucose; Body Mass Index; Cross-Over Studies; Epinephrine; Exercise; Fatty Acids, Nones	2003
Post-exercise increase of lipid oxidation after a moderate exercise bout in untrained healthy obese men. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2003, Volume: 35, Issue:2 Topics: Adult; Blood Glucose; Body Mass Index; Cross-Over Studies; Epinephrine; Exercise; Fatty Acids, Nones	2003
Post-exercise increase of lipid oxidation after a moderate exercise bout in untrained healthy obese men. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2003, Volume: 35, Issue:2 Topics: Adult; Blood Glucose; Body Mass Index; Cross-Over Studies; Epinephrine; Exercise; Fatty Acids, Nones	2003
Effect of endurance training on adrenergic control of lipolysis in adipose tissue of obese women. The Journal of clinical endocrinology and metabolism, 2004, Volume: 89, Issue:3 Topics: Abdomen; Adipose Tissue; Adrenergic Agonists; Adult; Blood Glucose; Body Mass Index; Epinephrine; Fa	2004
Angiotensin II-induced effects on adipose and skeletal muscle tissue blood flow and lipolysis in normal-weight and obese subjects. The Journal of clinical endocrinology and metabolism, 2004, Volume: 89, Issue:6 Topics: Adipose Tissue; Angiotensin II; Body Weight; Central Nervous System Depressants; Drug Interactions;	2004
Are peristaltic pumps as reliable as syringe pumps for metabolic research? Assessment of accuracy, precision, and metabolic kinetics. Metabolism: clinical and experimental, 2004, Volume: 53, Issue:7 Topics: Adult; Female; Glycerol; Humans; Infusion Pumps; Metabolism; Obesity; Reproducibility of Results; Re	2004
Comparison of the acute pharmacodynamic responses after single doses of ephedrine or sibutramine in healthy, overweight volunteers. International journal of clinical pharmacology and therapeutics, 2004, Volume: 42, Issue:8 Topics: Adult; Anti-Obesity Agents; Basal Metabolism; Blood Glucose; Blood Pressure; Body Composition; Body	2004
Dairy augmentation of total and central fat loss in obese subjects. International journal of obesity (2005), 2005, Volume: 29, Issue:4 Topics: Adolescent; Adult; Analysis of Variance; Animals; Blood Glucose; Blood Pressure; Body Composition; C	2005
Influences of AT1 receptor blockade on tissue metabolism in obese men. American journal of physiology. Regulatory, integrative and comparative physiology, 2006, Volume: 290, Issue:1 Topics: Adipose Tissue; Adult; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cross-Over Studi	2006
Colonic fermentation from lactulose inhibits lipolysis in overweight subjects. American journal of physiology. Endocrinology and metabolism, 2005, Volume: 289, Issue:4 Topics: Acetates; Administration, Oral; Colon; Diet Therapy; Fatty Acids, Nonesterified; Female; Fermentatio	2005
Studies of phosphodiesterase effects on adipose tissue metabolism in obese subjects by the microdialysis technique. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2005, Volume: 56, Issue:3 Topics: Adipose Tissue; Adrenergic alpha-Agonists; Adult; Cyclic AMP; Electric Impedance; Female; Glucose; G	2005
Dynamic strength training improves insulin sensitivity and functional balance between adrenergic alpha 2A and beta pathways in subcutaneous adipose tissue of obese subjects. Diabetologia, 2005, Volume: 48, Issue:12 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Recept	2005
The effect of oral glucose loads on tissue metabolism during angiotensin II receptor and beta-receptor blockade in obese hypertensive subjects. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2006, Volume: 38, Issue:5 Topics: Adipose Tissue; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blo	2006
The acute effects of different sources of dietary calcium on postprandial energy metabolism. The British journal of nutrition, 2006, Volume: 96, Issue:1 Topics: Aged; Blood Glucose; Calcium Citrate; Calcium, Dietary; Carbohydrate Metabolism; Cross-Over Studies;	2006
Dissociation between adipose nitric oxide synthase expression and tissue metabolism. The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:7 Topics: Adipose Tissue; Adrenergic beta-Agonists; Adult; Body Weight; Enzyme Inhibitors; Gene Expression Reg	2007
Effect of beta-adrenergic stimulation on whole-body and abdominal subcutaneous adipose tissue lipolysis in lean and obese men. Diabetologia, 2008, Volume: 51, Issue:2 Topics: Adipose Tissue; Adrenergic beta-Agonists; Adult; Body Composition; Body Mass Index; Fasting; Fatty A	2008
Effects of glycerol addition to diet in weight-reducing clubs. International journal of obesity, 1984, Volume: 8, Issue:2 Topics: Adult; Aged; Body Weight; Diet, Reducing; Female; Glycerol; Humans; Hunger; Middle Aged; Obesity; Pi	1984
Persistent lipolytic effect of exogenous growth hormone during caloric restriction. The American journal of medicine, 1995, Volume: 98, Issue:2 Topics: Adipose Tissue; Adult; Body Composition; Diet, Reducing; Energy Intake; Fatty Acids; Female; Glycero	1995
A comparison of the thermogenic, metabolic and haemodynamic responses to infused adrenaline in lean and obese subjects. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1994, Volume: 18, Issue:11 Topics: Adult; Blood Glucose; Blood Pressure; Body Temperature Regulation; Energy Metabolism; Epinephrine; F	1994
Acute pharmacologic blockade of lipolysis normalizes nocturnal growth hormone levels and pulsatility in obese subjects. Metabolism: clinical and experimental, 1994, Volume: 43, Issue:10 Topics: Administration, Oral; Adult; Blood Glucose; Body Mass Index; Circadian Rhythm; Cross-Over Studies; D	1994
Evidence for an abnormal postprandial response to a high-fat meal in women predisposed to obesity. The American journal of physiology, 1994, Volume: 267, Issue:4 Pt 1 Topics: Adult; Dietary Fats; Disease Susceptibility; Eating; Energy Metabolism; Fatty Acids, Nonesterified;	1994
Insulin sensitivity and lipid levels in obese subjects after slimming diets with different complex and simple carbohydrate content. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1993, Volume: 17, Issue:7 Topics: Adult; Blood Glucose; Diet, Reducing; Dietary Carbohydrates; Dietary Fiber; Glucose Clamp Technique;	1993
Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. The Journal of clinical endocrinology and metabolism, 1996, Volume: 81, Issue:10 Topics: 3-Hydroxybutyric Acid; Appetite Depressants; Body Weight; C-Peptide; Diabetes Mellitus; Diabetes Mel	1996
Lactate and glycerol release from the subcutaneous adipose tissue of obese urban women from South Africa; important metabolic implications. The Journal of clinical endocrinology and metabolism, 1998, Volume: 83, Issue:11 Topics: Adipose Tissue; Adult; Black People; Blood Flow Velocity; Body Constitution; Female; Glucose; Glycer	1998
Sympathetic modulation of lipolysis in subcutaneous adipose tissue: effects of gender and energy restriction. The Journal of laboratory and clinical medicine, 1999, Volume: 134, Issue:1 Topics: Abdomen; Adipose Tissue; Adrenergic Agents; Adult; Energy Intake; Epinephrine; Female; Glycerol; Hum	1999
Effects of 10 days of endurance exercise training on the suppression of whole body and regional lipolysis by insulin. The Journal of clinical endocrinology and metabolism, 2000, Volume: 85, Issue:4 Topics: Adipose Tissue; Blood Glucose; Body Composition; Deuterium; Exercise; Female; Glucose Clamp Techniqu	2000
The effect of exercise training on beta-adrenergic stimulation of fat metabolism in obese men. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2001, Volume: 25, Issue:1 Topics: Adrenergic beta-Agonists; Adult; Body Composition; Energy Metabolism; Exercise; Glycerol; Humans; Is	2001
Acute fructose administration improves oral glucose tolerance in adults with type 2 diabetes. Diabetes care, 2001, Volume: 24, Issue:11 Topics: Adult; Area Under Curve; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids, N	2001
Acute fructose administration improves oral glucose tolerance in adults with type 2 diabetes. Diabetes care, 2001, Volume: 24, Issue:11 Topics: Adult; Area Under Curve; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids, N	2001
Acute fructose administration improves oral glucose tolerance in adults with type 2 diabetes. Diabetes care, 2001, Volume: 24, Issue:11 Topics: Adult; Area Under Curve; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids, N	2001
Acute fructose administration improves oral glucose tolerance in adults with type 2 diabetes. Diabetes care, 2001, Volume: 24, Issue:11 Topics: Adult; Area Under Curve; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids, N	2001
In vivo alpha(1)-adrenergic lipolytic activity in subcutaneous adipose tissue of obese subjects. The Journal of pharmacology and experimental therapeutics, 2002, Volume: 301, Issue:1 Topics: Adipose Tissue; Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-1 Receptor Antagonists; Adren	2002
Physical training in human hyperplastic obesity. IV. Effects on the hormonal status. Metabolism: clinical and experimental, 1977, Volume: 26, Issue:3 Topics: Adult; Blood Glucose; Body Composition; Clinical Trials as Topic; Epinephrine; Fatty Acids, Nonester	1977
[Glucose tolerance, insulin and lipids after one week's administration of fenfluramine to overweight patients (author's transl)]. MMW, Munchener medizinische Wochenschrift, 1975, Nov-28, Volume: 117, Issue:48 Topics: Adult; Blood Glucose; Body Weight; Cholesterol; Fatty Acids, Nonesterified; Fenfluramine; Glucose To	1975
Hormonal and metabolic studies of the action of fenfluramine in normal man, obesity, acromegaly and diabetes mellitus. Postgraduate medical journal, 1975, Volume: 51 Suppl 1 Topics: Acromegaly; Adult; Aged; Blood Glucose; Diabetes Mellitus; Fatty Acids, Nonesterified; Female; Fenfl	1975
Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects. Diabetes, 1992, Volume: 41, Issue:11 Topics: 3-Hydroxybutyric Acid; Alanine; Blood Glucose; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Ty	1992
A 24-h energy expenditure study on reduced-obese and nonobese women: effect of beta-blockade. The American journal of clinical nutrition, 1992, Volume: 56, Issue:4 Topics: Adult; Blood Glucose; Body Composition; Body Mass Index; Carbohydrate Metabolism; Energy Metabolism;	1992
Does yohimbine act as a slimming drug? Israel journal of medical sciences, 1991, Volume: 27, Issue:10 Topics: Adult; Combined Modality Therapy; Diet, Reducing; Double-Blind Method; Energy Metabolism; Exercise;	1991
Metabolic effects and body fat mass changes in obese subjects on a very-low-calorie diet with and without intensive physical training. Annals of nutrition & metabolism, 1987, Volume: 31, Issue:6 Topics: Adipose Tissue; Catecholamines; Combined Modality Therapy; Diet, Reducing; Exercise Therapy; Fatty A	1987
Free fatty acids, glycerol and alveolar acetone in obese women during phenformin treatment. Acta medica Scandinavica, 1968, Volume: 184, Issue:4 Topics: Acetone; Adult; Aged; Air; Clinical Trials as Topic; Fatty Acids, Nonesterified; Female; Glycerol; H	1968
The interaction of diabetes and obesity on the regulation of fat mobilization in man. Diabetes, 1969, Volume: 18, Issue:11 Topics: Adult; Body Weight; Clinical Trials as Topic; Diabetes Mellitus; Dietary Carbohydrates; Fatty Acids,	1969
[Lipid and carbohydrate metabolites in the blood of normal and obese subjects following intravenous administration of insulin, with special attention to the counterregulatory phases]. Endokrinologie, 1970, Volume: 57, Issue:1 Topics: Acetoacetates; Adolescent; Adult; Blood Glucose; Clinical Trials as Topic; Fatty Acids, Nonesterifie	1970
Hyperinsulinemia secondary to chronic administration of mazindol and d-amphetamine. The American journal of the medical sciences, 1971, Volume: 261, Issue:6 Topics: Acetoacetates; Adult; Amphetamine; Appetite Depressants; Blood Glucose; Body Weight; Cholesterol; Cl	1971

glycerol and Obesity

Research Excerpts

Research

Studies (469)

Authors

Clinical Trials (20)

Trial Overview

Trial Outcomes

Change in Glycerol Enrichment

Baseline Glucose Disposal - a Measure of the Body's Ability to Process Sugars.

Baseline Plasma Leptin Concentrations

Post-treatment Glucose Disposal. I.e. Glucose Disposal After Treatment With Leptin or Placebo.

Post-treatment Plasma Leptin Levels

Change From Baseline in Cerebrospinal Fluid Amyloid β40 Concentration at 52 Weeks

Change From Baseline in Volumetric Magnetic Resonance Imaging (MRI)

Change in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)

Number of Adverse Events

Comparison of the Response to Treatment of Resveratrol Based on ApoE Genotype

Basal, Postabsorptive Fractional Synthesis Rates of Muscle Protein Synthesis

Very-Low Density Lipoprotein-Triglyceride (VLDL-TG) Concentration

Very-Low Density Lipoprotein-Triglyceride (VLDL-TG) Concentration

Very-Low Density Lipoprotein-Triglyceride (VLDL-TG) Secretion Rate

Very-Low Density Lipoprotein-Triglyceride (VLDL-TG) Secretion Rate

VLDL-TG Plasma Clearance Rate (Means)

VLDL-TG Plasma Clearance Rate (Means)

VLDL-TG Plasma Clearance Rate (Medians)

VLDL-TG Plasma Clearance Rate (Medians)

Reviews

Trials

Other Studies

Authors	Studies
Choi, WG	1
Choi, W	1
Oh, TJ	1
Cha, HN	1
Hwang, I	1
Lee, YK	1
Lee, SY	2
Shin, H	1
Lim, A	1
Ryu, D	2
Suh, JM	1
Park, SY	1
Choi, SH	1
Kim, H	3
Heil, LBB	1
Cruz, FF	1
Antunes, MA	1
Braga, CL	1
Agra, LC	1
Bose Leão, RM	1
Abreu, SC	1
Pelosi, P	1
Silva, PL	1
Rocco, PRM	1
Truelsen, SF	1
Missel, JW	1
Gotfryd, K	1
Pedersen, PA	1
Gourdon, P	1
Lindorff-Larsen, K	1
Hélix-Nielsen, C	1
Al-Mass, A	1
Poursharifi, P	1
Peyot, ML	1
Lussier, R	1
Levens, EJ	1
Guida, J	1
Mugabo, Y	1
Possik, E	1
Ahmad, R	1